

Particular Aspects on Applying Nanocarbon Quantum Dots for HIV Inhibition and Theranostics: a Review

Yaung Kwee, Alfinda Novi Kristanti* and Mochamad Zakki Fahmi

¹Department of Chemistry, Universitas Airlangga, Surabaya 60115, Indonesia.


²Supramodification Nano-micro Engineering Research Group, Universitas Airlangga, Surabaya 60115, Indonesia.

m.zakki.fahmi@fst.unair.ac.id and alvinda-n-k@fst.unair.ac.id*

(Received on 15th August 2020, accepted in revised form 28th April 2021)

Summary: Viral infection is a globally leading health issue, causing significantly unfavourable mortality with an adversely decreasing socio-economic growth. To solve those infections of global pandemic HIV specifically, the current utilization of highly active antiretroviral therapy (HAART) in human deficiency virus (HIV) theranostics has remarkably improved the life's duration of patients infected by human immunodeficiency virus (HIV); however, the unfortunate drawbacks in combination with prolonged HAART therapy need to be used continuously along patient's lifetime. Additionally, RNA virus of COVID-19 is also associated with viral pneumonia and acute respiratory distress syndrome causing significant morbidity and mortality. Meanwhile, many scientific researchers have explored the successive novelty of carbon quantum dots (CQDs) as alternative to HIV or other related viruses theranostics in the field of antiviral drugs research, but the attempt has been still challenging to introduce perfect antiviral CQDs with excellent biocompatibility, drug resistance, and safety at several areas in the virus's life cycle. On the contrary, CQDs-based nano-therapy is currently promising because those carbon quantum dots had multiple favourable properties, including significant antiviral response effects, water-soluble activity, color-tunable fluorescence, high yield, low cytotoxic behaviour, and promising biocompatibility. In this review, some effectively recent progress of promising CQDs for viral inhibition and theranostics explored by many studies are systematically summarized.

Keywords: HIV, CQD-based therapy, Nanomedicine, HIV, Antiviral activity.



Scheme-1: A simple schematic diagram of carbon-based dots attacking RNA virus and inhibiting the viral attachment to the Host Cell.

Introduction

Since the 1980s, the AIDS/ HIV pandemic has spread out all over the world; attacking 33 million people with more than 3 million people new cases infection and 2 million people of the death rate have been increasing each year. Newly infected patients of approximately 7400 were increasing per day in 2008 and the pandemic has kept going on [1]. The common drug delivery systems together with highly active antiretroviral therapy (HAART) can increase the longevity of AIDS/HIV-infected patients. Nevertheless, there are still various challenges remaining including the fact that the virus cannot be eliminated completely due to some considerable restrictions. There is the main problem that the treatment has failed because of poor patient compliance [2]. Hence, a nanotechnological approach has largely emerged as the opportunistic alternative.

Nanotechnology has been developing for using prominent small particles and their dimensions are as small as nanometer (10^{-9} or one billionth of a meter) [3]. Nanobiotechnology is connected to the definition and relation of nanoscience and biological knowledge, whereas another corresponding area is called 'nanomedicine' interacts with using nanostructured materials to theranostics of many diseases [4]. This technology has been emerging as an integrative study that has the promising progress to fundamentally enhance the remedy and inhibition of HIV/AIDS [5]. Since the last decade, the extensive applications of nanotechnology in several biomedical fields have promised great efforts of research [6]. The crucially opportunistic strengths of using nanomedicine over traditional HIV treatment and prevention are being capable of incorporating, encapsulating, or conjugating with various drugs to definitely trace cell-populated areas and to specifically pass tuneable drug release site [6]. Moreover, there are some benefits to accelerate their antiviral mode of action by many mechanisms: small size of particles (which can help drug delivery go into bodily certain areas) [7], extended surface sites to volume ratios (which enables to accommodate large-scale loading drugs) [8], and charge-adjustable behaviour (to promote the entrance of cells over the negatively charged cellular membrane), and exert nanoparticles to become appealing for viral treatment [9]. Nanoparticles like silver nanoparticles [10], and dendrimers include biomimetic properties [11, 12], which provide intrinsic antiviral properties. The encapsulation, surface functionalization, and structural modifications can lead to optimized drug

dosing, which can enhance the delivery system of stability and specificity to anatomically privileged cellular sites, targeted tissues, or subcellular compartments [13].

Nanomedicine, using nanoscale materials aims to prevent and treat various viral diseases, and such a method is known as "theranostics" [14]. In addition, using nanotechnology or nanomedicine for HIV/AIDS treatment, there are also the alternative applications of gene therapy [15], immunotherapy [16], and vaccine delivery [17]. Moreover, nanotechnology platforms for HIV/AIDS theranostics involve polymer nanoparticles [18], liposomes [19], dendrimers [20], nano-emulsions [21] and nanosuspensions [22]. All of those nanomedicine-based therapies have considerable efforts and some advantages to fight the viral threat to a greater extent except they still need to improve solubility, good patient adherence, good biostability, and bioavailability. Moreover, nano-based particles have been synthesized for the use of HIV therapeutics like noble metals-attributed drug-delivering agents [23], polymers [24], composite materials [25], and lipids [26]. Nevertheless, these nanoparticles also have limited use due to toxicity, their inert properties of starting material, colloidal stability, and complicated synthesized approaches. Consequently, many outstanding novel types of research have been stepped up to diminish the health problem of many virus-infected people around the world. The lethal viruses usually infected by people are the acquired immune deficiency syndrome/the human immunodeficiency virus (AIDS/HIV) [27], dengue virus (DENV), Ebola virus (EBOV), and the terrible pulmonary syndrome coronavirus (SARS-CoV) [28]. The SARS-COVID-19 is now terribly spreading around the world. The novel strain (SARS-CoV-2) caused pneumonia that seriously caused lung injuries. To reduce that infectious disease transmission, suitable methods are required based on the nature of the disease and mode of transmission [29].

As an added disadvantage, most of obtained research products have failed to use in the real-life medical trials because of toxic problems and vaginal irritation, being more vulnerable to sexually transmitted infections rather than supplying prevention [30]. Therefore, it is essential to find the development of alternative anti-HIV approaches,

which can profitably increase AIDS/ HIV remedy [31]. In this way, the use of carbon-based nanomaterials, in particular, carbon quantum dots (CQDs), have occupied considerable interest as promising nano-sized particles for the drug delivery tool in biomedical uses [32]. Carbon quantum dots (CQDs) are nano-crystals; their morphological studies have zero-dimensional materials and their sizes are smaller than 10 nm [33]. The well-known investigated carbon quantum dots showed spherical carbon nanomaterials with their unique properties, including favourable photoluminescence, good aqueous dispersibility, outstanding biocompatibility, chemical inertness, photostability against photo-bleaching, cost-effective synthesis, good elasticity in modification and low toxicity as well [34]. Moreover, they are extensively used in the field of bio-imaging enhancement [35], bio-sensing platform [36], bio-labelling appeal to detect contaminants of chemical ions [37], photodynamic therapy technique [38], drug-delivering remedy [39], and viral treatment as well [40]. CQDs also have tuneable fluorescence and manageable their surface sites, which can improve the adsorption capability, which corresponded to adhere multiple biological areas in order to inhibit various viruses [41].

CQDs which are in the form of graphene-like nanostructure have been shown to have promising good results due to potential properties mentioned above and their high affinity of multifunctional groups to various specific cellular sites [42]. There are some literature review articles concerning nanotechnology approaches for HIV treatment and prevention reported by [43-48], respectively.

However, as far as it can be known, studies of carbon-based nanomaterials (CQDs) for HIV theranostics have not been widely reviewed. Valizadeh, 2015 has reported that only optically diagnostic HIV with nanomaterials focused on the detection of serum biomarkers of the blood-borne contagious infections applying surface-upgraded Raman scattering (SERS) and Surface Plasmon Resonance (SPR) [49]. The current review differs from that approach because many studies of carbon-based nanomaterials and other nanoparticles have been extensively demonstrated for both inhibition and theranostics for HIV to suppress the binding or the interaction between the gp120 and receptor CD4 and co-receptors (CCR5 or CXCR4) in the T cell,

thereby blocking the viral entry and replication. The current review aims to largely outline the potential of the multidisciplinary field of carbon-based nanomaterials and nanoparticles to enhance the field of HIV treatment and prevention.

Current Antiretroviral Therapy in HIV

Antiretroviral therapy, known as ART is meant that the treatment method of the HIV by combining medicines [50]. The combination with three or more antiretroviral drugs was used as "Highly active antiretroviral therapy (HAART)" so that the viral burden in a patient could be suppressed to effectively detectable levels (*i.e.* <50 copies of virus/mL of blood) and require to supply those drugs to patients simultaneously [51]. Additionally, the utilization of the highly active antiretroviral therapy (HAART) prepared from integrated three or more drugs focused on complex steps of the HIV biorhythm; it has paid the significant improvement to AIDS/ HIV-infected patients' life expectancy and lifestyle [31]. Although the conventional HAART treatment for HIV/AIDS has been used successfully, a few hurdles are remaining. The main issue is the failure of giving treatment to patients, definitely due to poor patient adherence to those drugs. Also, this combination therapy is necessary for infected patients to always be taken so as to avoid re-occurrence of HIV from quiescently infected cells. Consequently, it brings severe side effects and is profitless where the virus matures hostility, often thereby resulting in clinical unsuccessfulness. Besides, the effectiveness of their many potential therapeutic agents is restricted due to their poor solvent-soluble property, and that solvent is required for their medication delivery and cytotoxicity consideration of those ART drugs [52, 53].

The antiretroviral therapy is mainly aimed at two objectives, such as virologic control (the measurement of HIV RNA or p24 antigen quantity reduction) and immune rehabilitation (CD4 count re-establishment). HAART therapeutics are generally classified by six categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), CCR5 and CD4 antagonists, and integrase strand transfer inhibitors (INSTIs) [54]. The currently antiretroviral drugs are shown on Table-1.

Table-1: Current Antiretroviral Drugs Utilized in the Remedy of HIV.

Classes	Drug Agents FDA approved	Mechanistic Mode of Action
Nucleotide Reverse Transcriptase Inhibitors (NtRTI)	Abacavir(ABC), Didanosine (DDI), Emtricitabine (FTC), Lamivudine (3TC), Stavudine (d4T), Zalcitabine (ddC), Zidovudine (AZT),	<ul style="list-style-type: none"> •Block the reverse transcriptase enzyme which manages the viral transformation from RNA to DNA inside the harbor cell. •Necessitate intracellular metabolism to their triphosphate identity, before activated action [55].
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)	Delavirdine (DLV) Efavirenz (EFV) Nevirapine (NVP)	<ul style="list-style-type: none"> •Non-competitive prevention of RT •Cohere immediately to RT and block DNA polymerase manner by impeding the synergistic plot of that enzyme. •Also prevent reverse transcriptase but intracellular activation is not required for activation [56].
Protease inhibitors	Atazanavir (ATV) Ritonavir (RTV) Lopinavir (LPV) Darunavir (DRV) Indinavir (IDV)	<ul style="list-style-type: none"> •Accountable for the cleavage of precursors of viral polypeptide complexity into useful proteins, required for the maturation and congregation of virions. •Impede the growth of new virions from incurably transmitted infection cells [57].
Integrase inhibitors	Raltegravir (RAL) Elvitegravir	<ul style="list-style-type: none"> •Impede the catalytic pursuit of HIV-1 integrase. •Inhibit the combination of linear HIV-1 DNA into the harbor cell genome by hindering stranded shifting [58].
CCR5 inhibitors	Maraviroc (MVC) Vicriviroc (VCV)	<ul style="list-style-type: none"> •Selectively adheres to the human chemokine, functioning receptor CCR5 •Prevent the inducement of CCR5 with the HIV-1 membrane glycoprotein gp120, which is essential for tropic HIV to enter T cells [59].
Fusion inhibitor	Enfuvirtide (ENF)	<ul style="list-style-type: none"> •Tie up the HIV-1 membrane glycoprotein gp41 and block the mingling of HIV with the harbor cell before the virus goes into the cell and initiates the replicating process [60].

Abbreviations: RNA, ribonucleic acid; DNA, Deoxynucleic acid; CCR5, chemokine coreceptor

Nano-Based Antiviral Therapy

Promising nanomaterials for antiviral agents are formulated for virus inhibition and theranostics because they have proven to exhibit antiviral activity against various viruses. Such nanoformulations are prepared from heavy metal nanoparticles, silver or gold nanoparticles, other nanoparticles including carbon-based nanoparticles. However, the toxicity is the main concern for drug delivery systems into targeted cell. Regarding different toxicities derived from respective silver or gold-based nanoparticles, heavy metal-based quantum dots and carbon-based dots, the carbon-based dots are relatively non-toxic. And hence, carbon-based dots have attained significant attention to formulate nano-based antiviral agents [40, 61].

Inorganic Nanoparticle

Theoretically, what kinds of prepared nanoparticles (NPs) we used and how they formed are crucial for the adaptable model of viral inhibition. Therefore, it requires a general overview of the antiviral activity of NPs produced from various types/kinds and configuration/ composition of nanomaterials [62]. Antiviral agents derived from nanoparticles are extensively modified from easy inorganic NPs into complicated organic and hybrid nanosystems or nanostructures. The composition of nanospheres, nanocapsules, and nanocages derived from metallic nanoparticles (MNPs) and

nanocomposites (NCs) could be divided by inorganic NPs (INPs), whereas organic NPs (ONPs) produce nanocapsules as in the typical shape of nanocomposites (NCs) with the modification of their chemical structure. Hybrid nanosystems or nanostructures are highly standardized by a mixture of either inorganic-organic or inorganic-inorganic (nanocomposites). The organic-organic nanoparticulated systems (lipid-polymer hybrid NPs) are standardized due to particular requirements of the delivery system to use at the targeted point [63, 64].

Inorganic nanoparticles have some significant properties, for instance, photoluminescence, good solubility, tuneable size, shape, long-term stability, large surface-to-volume ratio, and attachment of multifunctional groups that have drawn the great attention for INPs in the biomedical field for numerous applications [65]. Of such applications, the widely investigated capability of INPs aims at displaying several surface binding sites and controlling their *in vivo* natural behaviour as well [66]. Recently, metal-based nanoparticles have been prepared for promising antiviral candidates in case of HIV-1 remedy, respiratory syncytial virus, hepatitis B virus, monkeypox virus, herpes simplex virus type 1, Tacaribe virus, and influenza virus [67].

The anti-HIV-1 responsive activities of these metal-based nanoparticles (gold/silver) are commonly studied (as shown on Table-2). Selecting the point to the reticuloendothelial system (RES)

tends to be opsonization (*i.e.*, agglomeration of effective nanoparticles in the RES), thereby activating the immunity via phagocytic functions. Those nanoparticles were delivered from intrinsic flowing movement, and thus assembling in the RES where the disease persistence of HIV remains [68]. However, there are some advantages of antiviral agents derived from inorganic nanoparticles to treat or prevent HIV. Moreover, gold and silver nanoparticles intrinsically exhibit antiviral effects to fight a large number of HIV-1 strains, behaving as viral inhibitory agents with the inhibition of post-entry phases of that HIV-1. Thus, the viral persistence could be weakened by these

nanoparticles[69, 70]. Inorganic-attributed nanoparticles expose highly optical, electronic, catalytic, and magnetic properties. Moreover, they have distinctive characteristics, including small nanometer sizes, tuneable imaging behaviour, and multifunctionality. To improve cytotoxicity to be safe, it is significantly important for nanoparticles to effectively modify their surfaces. In other words, there are a few limitations for Au/Ag nanoparticles: highly toxic problems in DNA destruction and cellular apoptosis, and then the effects of AgNPs on such different toxicities may be a consequence of their ability to inflict cell damage [71-74].

Table-2: Various Nanoparticles Derived Multi-Viral Theranostics.

Nanoparticles	Typical Virus	Model of Cells	Mechanism of Antiviral Action	Purpose	References
Silver (Ag) AgNPs	HIV-1	HeLa-CD4-LTR- β -gal cells, MT-2 cells, Lymphoid human cell line	•Interconnection with gp120 to hinder CD4-based virion adhering, mingling, and pathogenesis	•To perform their antiviral property level in case of HIV-1 following a trial of individual <i>in vitro</i> assays	[75]
AgNPs	Avian influenza A virus, subtype H ₇ N ₃	Vero cells	•Obstructing HA mode of action and deviating interrelation with viral propagation route	•To inhibit the viral entrance, thereby distorting viral propagation	[76]
AgNPs	Poliovirus type-1	Human Rhabdomyosarcoma	•Interconnection with viral protein can weaken the interrelation with the T cell	•To inhibit viral penetration	[77]
AgNPs	Murine norovirus-1	RAW 264.7 cells	-	•To serve as virucidal agents	[78]
AgNPs	Infectious Bursal Disease (IBD) virus	Embryonated chicken eggs	•Interrelated with viral covering	•To inhibit viral entry and replication	[79]
AgNPs	S. cerevisiae dsRNA viruses	HeLa cells, NIH/3T3 cells	•Interact with viral genome and prohibit viral propagation	•To inactivate or destroy viruses	[80]
AgNPs	Hepatitis B virus	HepAD38 cell line	•Silver nanoparticles could prevent the <i>in vitro</i> growth of HBV RNA and extracellular virion	•For viral therapy	[81]
Graphene Oxide-Silver Nanocomposites (GO-AgNPs)	HIV-1 RNA virus, PEDV (a member of the family <i>Coronaviridae</i>)	MARC-145 cells	•GO-AgNPs nanocomposites distinctively obstruct the virus entrance into harbor cells, consequently, restrain virus propagation.	•To boost viral inhibition	[82]
Titanium (Ti) Nanoparticles TiO ₂ NPs	H ₃ N ₂	-	•Directly contacted with virus	•To use as virucidal agent	[83]
TiO ₂ -DNA Loaded nanocomposites DNA	H ₁ N ₁ , H ₅ N ₁ , and H ₃ N ₂	MDCK cells	•Selectively adhere to hidebound areas in the viral genetic makeup and prevention of viral replication	• To act as viral inhibition	[84]
TiO ₂ NPs	MS2, PRD1, Φ X174, Fr	-	•Interconnection with the viral shell of protein (glycine, alanine, and proline remnants)	• To exert photocatalytic deactivation of bacteriophage	[85]
Gold Nanoparticles Au NPs	HIV-1	HeLa-CD4-LTR-Bgal cell	•Attaching with viral glycoprotein (gp120) and inhibit CD4 binding	•To inhibit viral entry	[86]
Au NPs	Foot- and- mouth diseases virus (FMDV)	BHK-21	•Hinder viral reproduction in accompany with transcription	•To perform as a virucidal agent	[87]
Au NPs	Influenza virus A (H1N1, H3N2)	-	•Peroxidase-mimic enzymatic interaction	•To detect the viral pathway	[88]
Gold NPs (AuNPs) Loaded with synthetic peptide (FMDV protein)	FMDV	BALB/c mice	•Antibody interposed immune resistance	•To be size-dependent booster of immune system	[89]
AuNPs DNAzyme (DDZ)	Dengue virus (DENV)	Aedes albopictus C6/36 cells	•DDZ triggering interposed salt induced accumulation of AuNPs	•To use in viral detection	[90]

AuNPs conjugated with siRNA	DENV	Vero cells	•Impeding viral propagation and releasing contagious virion	•To use as efficient delivering agents for viral prevention	[91]
AuNPs loaded Viral matrix 2 protein (M2e)	H ₁ N ₁	BALB/c female mice	•Antibody interposed CpG (cytosineguanine rich oligonucleotide) immune activity	•As a influenza vaccine	[92]
AuNPs loaded recombinant trimetric A/Aichi/2/68 (H3N2), Hemagglutinin (HA) and TLR5 agonist flagellin (FlC)	H ₃ N ₂	Female BALB/c mice, HEK 293 T cells, JAWS II cells	•Antigen-specific T cell- interposed immune capability	•To improve the booster of immune system	[93]
AuNPs loaded monoclonal anti-hemagglutinin antibody (mAb)	H ₃ N ₂	-	•Viral surface removal with NPs-mAb	•To use as a colorimetric immunosensor viral detection	[94]
AuNPs load viral consensus matrix 2 peptide (M2e)	H ₁ N ₁ , H ₃ N ₂ , H ₅ N ₁	BALB/c mice	•Highly humoral and cellular response	•To serve as the comprehensive influenza A vaccine	[95]
AuNPs loaded recombinant viral Hemagglutinin (HA)	H ₃ N ₂	BALB/c mice	•Stronger degree of viral-specified IgA and IgG, advanced level of antigen certain interferon- γ (IFN- γ)-release, CD4+ cell growth and stimulating high effect or CD8+ T cell	•To enhance mucosal cellular immune capacity	[96]
Au nanoparticles capped with mercaptothanesulfonate (Au-MES NPs)	Herpes simplex virus type 1	Vero cell	•Obstruct the viral attachment, entrance, and cell-to-cell distribution, suggesting that the Au-MESNPs can possibly be helpful for both a prophylactic and therapeutic candidate.	•To use an antiviral therapeutic agent	[97]

Abbreviations: CD4, cluster of differentiation 4; HA, hemagglutinin protein; FMDV, Foot-and-mouth disease virus; IgG, Immunoglobulin G; IgA, Immunoglobulin A

Organic Nanoparticles

Organic nanoparticles are very commonly useful for drug delivery, and become one of the most popular investigated platforms of nanoparticles. They also have promising properties to be used extensively in the biomedical field for a therapeutic system in humans [98]. The most widely used categories of organic nanoparticles are polymeric nanoparticles, nanocapsules, nanospheres, liposomes, micelles, and dendrimers [99].

First, polymeric nanoparticles seem to be colloidal solids and their dimensions range from 10 to 100 nm. The capillary penetration to tissue is helpful and uptake by cells due to their small size, resulting in enhanced concentrations at target cellular areas. Polymer-based nanoparticles with biologically active factors are soluble, entrapped, and encapsulated into naturally synthesized polymer nanomaterials. Polymers, for example, polyglycolides, polylactides, poly (lactide-co-glycosides), polyorthoesters, polyanhydrides, polycyanoacrylates, and polycaprolactone are commonly used in medicine and pharmaceuticals with the approval of the World Health Organization (WHO) and the Food and Drug Administration (FDA). Polymeric nanoparticles have some agreeable advantages - chemically precise composition,

remarkably promising physical properties (dissociated controlled rate, permeability, deterioration, eroding, and targeting efficacy), no toxicity, and lack of leachable or harmful impurities. Since they have their excellent biocompatibility and biodegradability signals, they are widely used for nanomedicine in clinical modes [100, 101, 102].

Second, nanocapsules are in the form of typically vacant domains, in which there is the drug's confinement to an internal gap, encapsulated by a polymeric covering. The average sizes range from 50 to 300 nm, and thus their tiny tenuity and fast-moving delivering rate could be identified [103]. De Oliveira *et al.* 2005 explored nanocapsules to be used to enhance drug distribution to confined antiviral brain tissue in accordance with the penetrability glycoprotein (P-gp) efflux carrier. They found that the HIV protease inhibitor, indinavir-loaded Solutol® HS15 nanocapsules exhibited highly enhanced cellular absorbing rate in the targeted brain site and testes of mice, in contrast with sample standard mice where alone indinavir solution was given in [104].

The third ones, nanospheres are in the typical form of a matrix where the drug is physically or correspondingly distributed, with the dimensional diameter ranging from 100 to 200 nm [105]. There

have been numerous research approaches of potential nanospheres to treat hepatitis B virus (HBV) [106], herpes simplex virus (HSV) [97], influenza [107], and also other inclusive review articles concerning viral prevention and treatment by using these bioactive agents were also presented [108].

Fourth, liposomes are formed as spherical carriers with its dimensions, which generally ranged from 20 to 30 nm [109]. They functioned as the traditional vesicular transporters, which consist of phospholipid molecules in the form of a lipid bilayer encircling an aqueous nucleus [110]. They are helpful for the encapsulation of hydrophilic drugs, whereas amphiphilic and hydrophobic drugs enable them to solubilize the phospholipid bilayers. Additional advantages are that circulating by speedy clearance makes the delivery of antiretrovirals strong entrapment capacity and a longer half-life in circulation within macrophages. Moreover, they are relatively safe and biodegradable [111]. As a disadvantage, liposomes have a few considerable hurdles. Despite being the small core volume, deliquescent drug-delivery capacity of liposomes is restricted. And hence, their continuous usage and physical or biological stability of the antiretroviral is limited [6].

Fifth, micelles possess colloidal dispersions with their dimensions normally varying from 5 to 100 nm, based on the typical configuration of head categories and length of the alkyl series. Micelles can be self-assembled into a structural conformation in an aqueous solution by interacting amphiphilic molecules themselves due to containing both hydrophobic and hydrophilic segments [112]. Polymeric micelles encapsulated by drugs have drawn great interest in nanotechnologies because these nanoformulations can increase both water solubility and stability. Micelles are beneficial in viral therapeutics, providing a slower and specific rate of dissociation or distribution. Thus, they promote a longer drug-withholding time. Finally, the drug would highly accumulate at the target site [6].

The sixth one of organic polymeric nanoparticles is dendrimers. Dendrimers are also

well-known polymeric platforms for their designated types and shapes, adaptability in the drug delivery system, and highly functionalized compositions. Their properties are similar to biomolecules [113]. They are composed of a branched three-dimensional architecture, standardized by connecting numerous monomeric segments. Those large numbers of monomeric units possess minimal polydispersity and great functionality. Numerous chemical components, interior sheets, and the multivalent aspects can be encapsulated by a characterized polyfunctional core of dendrimers. The properties of dendrimers also rely on the multivalent site on the exterior composition. The characteristics of dendrimers can be maintained physically and chemically during the synthetic work by identifying the central categories, the intensity of the surface branch, and the naturally functional groups on the surface sites [114, 115].

At last, one of the promising organic polymers for use of the drug-loading system is solid lipid nanoparticles (SLNs). SLNs also functions in the drug delivery system as novel lipid-based nanocarriers with the average size in the range of 10 - 1000nm. SLNs have interesting features for therapeutic goals [116]. They are noticeably advantageous because they are synthesized from pre-physiologically well-tolerated lipids. They are also effective for good biocompatibility and low toxicity. Interestingly, the delivery system of solid lipid nanoparticles is better enhanced by lipophilic drugs, and thus the system is physically stable. Solid lipid nanoparticles are one of the promising colloidal transporter systems as alternative agents to polymers which are generally similar to the oil in water-emulsified procedure for administrating intravenous nutrition [117].

The nanoparticulate antiviral usages up to 2010 mainly comprised of nanoparticles (NPs), nanospheres, nanosuspensions, nano-emulsions, micelles, liposomes, dendrimers, solid lipid NPs (SLNs), nanogels, and cyclodextrin-based systems as well [43]. They are standardized as alternative supporting materials for antiviral therapy and part of their summary is listed on Table-3.

Table-3: Various Nano-Based Materials Come About for Antiviral Drugs Agents.

Organic Nanoparticles				
Nanoplatform Type	Characteristic virtues (Size, Morphology, Toxicity, etc.)	Drug	Virus Type	References
HPAC	<ul style="list-style-type: none"> •No toxicity in treating with different concentrations of HPAC in human epithelial cells (corneal, vaginal); • Average proliferation rate>75% following HeLa cells, foreskin fibroblasts; 	ACV	HSV	[118]
PLGA	<ul style="list-style-type: none"> •Drug-loading capacity 99%; •Three GCV pro-drugs was individually inserted into PLGA NPs; • Uniform-sized NPs • Mean diameter 116 - 143 nm; •Zeta potential between -13.8 and -15 mv; • Non-toxic PLGA-NPs treated with three individual concentrations for 24 h and 48 h in HCEC cell; 	GCV	HSV-1	[119]
PEG-PLGA	<ul style="list-style-type: none"> •Uniform sphere-shaped NPs; •Diphyllin-loaded NPs 178 nm, whereas bafilomycin-loaded ones 197 nm; •Biocompatible results and antiviral effects for the drugs-loaded NPs are significantly stronger than the free drugs; 	Diphyllin and Bafilomycin	H1N1	[120]
Tf-Albumin-PEG	<ul style="list-style-type: none"> •Uniform-sized NPs with average size ranging from 114 to 124 nm; •A negatively charged NPs surface 	AZT	-	[121]
HAS +copolymes of maleic anhydride/ Alkyl vinyl ethers of oligo (ethylene-glycol)	<ul style="list-style-type: none"> •NPs sizes ranged from 100 to 300 nm; •Surface sites of functional components can provide affinities of liver cells receptors; 	INFs-α	HIV	[122]
PLGA NPs	<ul style="list-style-type: none"> •LAM-loaded polydispersible NPs ranged from 221 to 250 nm; •Zeta potential in the range of -4.64 and -3.65 mv; •The loading capacity of LAM and the polymer was provided by FTIR and DSC; •Slowly degradable NPs in affected intestinal fluid PBS; 	LAM	-	[123]
Hybrid NPs (PLGA, MMA-SPM,PLA and PMMA)	<ul style="list-style-type: none"> •Particle size of PLGA ranged in 58–224 nm, whereas particle size of MMA-SPM ranged in 91–823 nm and nearly sphere-shaped NPs; • Non-cytotoxic NPs (male mice); 	LAM+AZT	-	[124]
PLGA-PEG	<ul style="list-style-type: none"> •All possess sphere-shaped NPs; •SAHA and NFV-loaded NPs sizes are 125 nm, while only NFV-loaded NPs range 118 nm and 119 nm for only SAHA-loaded NPs, respectively; •Non-toxic behavior of drugs-loaded NPs (tested on ACH-2 cells); 	SAHA NFV	HIV	[125]
PLGA	<ul style="list-style-type: none"> •Uniform-sized and surface-smooth NPs NFV-loaded NPs ranged approximately 185 nm; belonged to nearly narrow-spread NPs; •Zeta potential is 28 mV; 	NFV	-	[126]
Lactoferrin	<ul style="list-style-type: none"> •Size of NPs 45–60 nm, hydrodynamic radius of 103 nm, zeta potential of -23 mV; •Polydispersible NPs; •Chemical stability of NPs confirmed by FTIR and DSC; 	EFV	-	[127]
Folic acid-conjugated-P407	<ul style="list-style-type: none"> •NPs are promising following the conjugation of folic acid with P407, in particular, the number of HIV-replication in mice cells noticeably reduced due to the involvement of drugs of ATV and RTV; 	ATV+RTV	-	[128]
PMA coated MNP	<ul style="list-style-type: none"> •Uniform-sized nanoparticles ranged 35.2 nm in accordance with their conjugation with ENF; zeta potential is -29 mV; •No toxicity was shown <i>in vitro</i> and <i>in vivo</i> treatment; 	ENF	-	[129]
pMBA-Au NPs	<ul style="list-style-type: none"> •Average NPs size ranged 1.8 nm; •Non-cytotoxic <i>in vitro</i> assay; 	RAL	-	[130]
PLGA	<ul style="list-style-type: none"> •Mean particle size of 138.3 nm and zeta potential approximately -13.7 mV; •NPs Drug-loaded NPs exhibited no toxicity in contrast with free NPs; 	EFV+Lopinavir+RTV	-	[131]
PLGA+Pluronic F127	<ul style="list-style-type: none"> •Clearly expressed polydisperse NPs with mean size ranging to 220 nm; •-19.2 mV is of their zeta potential; •No serious toxicity within a 14 days pharmacokinetic treatment on mice; 	TAF+EVG	HIV	[132]
Lactoferrin	<ul style="list-style-type: none"> •Mean size of drug-loaded nanomaterials is around 67 nm; •No significant toxicity to red blood cells <i>in vitro</i>; •Developed bioavailability of the three drugs; 	AZT+EFV+LAM	HIV	[133]
Nanospheres Cs	<ul style="list-style-type: none"> •Spherical NS with a fully smooth surface; •Mean size of approximately 200 nm, polydispersible NS formation, •Zeta potential approximately 40 mV; •ACV encapsulated capacity is 86% •Agreeable Vero cell viability after treated with NS; 	ACV	HSV	[134]
Nanosuspensions Zirconium oxide beads	<ul style="list-style-type: none"> •Average particle size approximately ranged 320 nm; 	EFV	HIV	[135]

stabilized with PVP, poloxamers, and SLS	<ul style="list-style-type: none"> •Zeta potential of -32.8 mV; •EFV bioavailability enhanced after associated with nanosuspensions (<i>in vivo</i>, rabbits); 			
Nanoemulsions				
Mucoadhesive NEs	<ul style="list-style-type: none"> •Relied on triacetin-oil, tween 20-surfactant,transcutol P-cosurfactant; •Sphere-shaped NPs sizes of 23–200 nm; •Non-cytotoxic and nonirritant nanoplatforms (New Zealand albino rabbit); 	GCV	HSV	[136]
Micelles				
Cs-g-oligo (NiPAam)	<ul style="list-style-type: none"> •Copolymers self-aggregation into multimicellar assembly with hydrodynamic diameter in the range of 330- 436 nm; •Zeta potential falls in the range of +7 to +22.8 mV; •Satisfactory mucoadhesion and cytocompatibility activities; 	EFV	HIV	[137]
Liposomes				
Reverse phase evaporation	<ul style="list-style-type: none"> •GCV amalgamated with PC/CH/NaDC soluble in chloroform/diethyl; •Sphere-shaped liposomes; •Particle sizes range 210–17 nm; •Zeta potential ranged -52.4 mV; •Polydispersible Liposome NPs; 	GCV	HSV	[138]
rHDL	<ul style="list-style-type: none"> •rDHL-ACV palmitate complicated size of 33.5 nm,approximately10 times<ACV-liposomes; 	ACV	HBV	[139]
Cationic	<ul style="list-style-type: none"> •Viral gene formulation decreased by 65–75% in liver cells after 48 hours of dosing at mice; 	siRNA	HCV	[140]
Immunoliposomes	<ul style="list-style-type: none"> •Viral release decreased by 81% and free viral particles neutralized <i>in vitro</i>; 	HIV gp 120 Folding inhibitor	HIV	[141]
Immunoliposomes	<ul style="list-style-type: none"> •<i>In vivo</i> the virus-infected resistance was improved; 	anti-CCR5 siRNA	HIV	[130]
Immunoliposomes	<ul style="list-style-type: none"> •Immunoliposomes with mean size between 100 and 120 nm; significantly effective to deliver concentrated indinavir; 	Indinavir	HIV	[142]
Dendrimers				
PG	<ul style="list-style-type: none"> •Non-cytotoxic peptide–PG conjugated <i>in vitro</i>; •Potential antiviral effect <i>in vitro</i>; 	Peptides	IAV	[143]
Alginate-PEG	<ul style="list-style-type: none"> •Dendritic morphology provided by TEM; •Hydrodynamic diameter between 601and782nm; •Zeta potential ranges between-45.8 and -65 mv; •88% and 98% of cell viability confirmed satisfactory biocompatibility and non-cytotoxic behavior (neuro cells, Hela cells, glioma cells); 	AZT	HIV	[144]
Solid Lipid Nanoparticles (SLNs)				
Bryostatatin-2	<ul style="list-style-type: none"> •Lipid-loaded nanoparticles can trigger latent HIV and can prohibit virus's distribution <i>in vitro</i>; 	NFV	HIV	[145]
PEG and phospholipids	<ul style="list-style-type: none"> •Drugs-loaded LNPs ranged between 33 and 68 nm and associated cell viability between is between 88% and 96%; 	ATV+RTV or ATV+RTV+TFV	HIV	[146]
DSPC+MPEG+DSPE	<ul style="list-style-type: none"> •NPs diameters range between 52 and 68 nm; •<i>In vivo</i> anti-HIV LNPS did not show internal reactions and animal platelet counts are up to normal limits. 	Liponavir+ RTV+TFV	HIV	[147]
Nanogels				
PVCLNGs	<ul style="list-style-type: none"> •TEM revealed that the size is between 40 and 50 nm. •At lower than 10 µg/mL, there is no cytotoxic response in the cervicovaginal epithelial cell line. 	VCL	HIV-1	[30]

Abbreviations: NRTIs, nucleoside and nucleotide reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase; HPAC, highly porous activated carbon; ACV, acyclovir; HSV, herpes simplex virus, PLGA, poly(lactic-co-glycolic acid); GCV, ganciclovir; PEG, polyethylene glycol; AZT, azidothymidine, INFs- α , intranasal fentanyl spray; LAM, levacetylmethadol; MMA-SPM, methylmethacrylate-Sulfopropylmethacrylate; SAHA, suberoylanilide hydroxamic acid; NFV, nelfinavir; EFV, efavirenz; ATV, atazanavir; RTV, ritonavir; PMA, paraformaldehyde; MNP, magnetic nanoparticles; HAS, human serum albumin; ENF, enfuvirtide; pMBA, p-mercaptobenzoic acid; RAL, raltegravir; Cs, chitosan; ACV, acyclovir; PVA, polyvinyl alcohol; PVP, polyvinylpyrrolidone; NEs, nanoemulsions; GCV, ganciclovir; rHDL, recombinant high density lipoproteins; ssDNA, single stranded DNA; siRNA, small interfering RNA; HBV, hepatitis B virus; HCV, hepatitis C virus; PG, poly(glutamic acid); IAV, influenza A virus; TFV, tenofovir; DSPC, distearoyl phosphatidylcholine; MPEG, methoxypoly(ethylene glycol); DSPE, distearoylphosphatidylethanolamine; PVCLNGs, poly(N-vinylcaprolactam) nanogels; TEM, transmission electron microscopy; SEM, scanning electron microscopy; FTIR: Fourier-transform infra-red; DSC, differential scanning calorimeter

Preparation and Properties of CQDs

Several carbon nanomaterials (CNMs) have been increasingly developed by advanced nanotechnology. The exploration of carbon-based materials has been widely improved since 1990. Namely, fullerene (C₆₀), carbon nano-onions (CNOs), carbon nanotubes (CNTs), carbon nanohorns (CNHs), nanodiamonds, graphene derivatives, and carbon dots (CDs) which were characterized [148]. Of these nanomaterials, carbon quantum dots are the most widely used because they have drawn great interest for their unique properties in multiple applications. Carbon quantum dots were unexpectedly reclaimed when single-walled nanotubes (SWCNTs) luminescent carbon-based nanomaterials were purified by the electrophoretic method in 2004 [149]. In 2006, Sun *et al.* 2006 standardized CQDs from graphite fine particles and cement dust particles by a laser ablation method [150]. Generally, the chemical composition and physical characteristics of carbon dots (also called carbon quantum dots) or graphene-based dots are closely alike those of graphene oxide. However, their average sizes (below 10 nm) and typical form of being quasi-spherical nanoparticles are slightly different from those of graphene oxide [150].

The synthetic action of carbon quantum dots (carbon dots) is generally developed by using two methodological methods such as top-down and bottom-up approaches. The top-down approach covers acid dehydration, laser-ablated synthesis, electrochemical or chemical oxidation, and arc discharge from carbon-based raw materials. On the contrary, the bottom-up method includes pyrolysis, thermal carbonization, microwave or ultrasonic treatments, and solvothermal treatment from various starting materials [151].

Due to their multiple and outstanding merits such as photoluminescence, color-tunable behaviour, biocompatibility, water solubility, low toxicity, cost-effective synthesis and good photostability against photo-bleaching, those photoluminescent carbon dots have numerous biomedical applications in vitro and in vivo assays for example, as biosensing agents, bioimaging candidates, biolabeling techniques, drug delivery systems, photodynamic diagnosis, and viral treatment functions [152]. Moreover, nano-sized carbon quantum dots (CQDs) have received tremendous attention in accordance with their promising tiny size, high fluorescence emission, chemical stability, and easy functionalization. Concerning their optical properties, CQDs have become fluorescent due to two reasons:

1) the fluorescence emission from bandgap conversion of conjugated π -domains and 2) the fluorescence from the surface deformity. The optical emission in the near-infrared (NIR) spectral range of wavelength emitted by CQDs can be effective for biomedical applications [153]. Gaining strong fluorescence depends on the high percentage of quantum yield (QY) generated by prepared CQDs [154]. The color-tunable fluorescence can be made in favour of the excitation wavelength. The intrinsically photoluminescent CQDs can be helpful for photocatalysis, biomedicine, solar energy conversion, photosensors, and light-emitting diodes (LEDs) [154].

Some research investigated by many researchers and their co-workers to approve the non-toxic behaviour of prepared carbon-based nanomaterials on various cell lines, for example, HepG2 cells [155], HeLa [156], 293T [157], and in vivo biocompatibility on zebrafish (*Danio rerio*) [158, 159] have been developed. Moreover, CQDs strongly showed a virtual fluorescence depending on wavelength emission by controlling their size [160]. The fluorescent level would be turned with respect to the wavelength emission from the strong ultraviolet to visible or the near-infrared range of wavelength. Besides, the surface sites of CQDs were functionalized by miniature organic compounds, metals, and scale-down polymers so that water-dispersible and nano-fluorescence properties would be enhanced [161].

CQDs exhibit their stable photoluminescence with drug/gene-loaded treatment so that they could, therefore, be used for drug-delivering agents [162], and for delivering genetic matter via electrostatic interaction [163], and siRNA [164]. In particular, CQDs with several functional components were utilized for the multipurpose nano-system for intracellular photoluminescence and subcellular targeting drug delivery [152].

Lately, Ge *et al.* 2015 have prepared CQDs as photodynamic therapy (PDT) agents with uncommon singlet molecular oxygen (¹O₂) fabrication and used as superior photoacoustic and thermal treatment of cancer cells in living administrating mice [165]. Those CQDs exhibited photodynamic and photothermal results when irradiated by laser upon 635 nm following the excellent photothermal conversion capacity. Besides, Chen *et al.* explored a photosensitiser an alternative PDT system using the two-photon absorbance of CQDs. The action mode of those CQDs effectively

exhibited strong induction of apoptosis in cancer HeLa cells when excited by around 700 nm [164].

Fahmi and co-workers have explored the promising carbon dots (CQDs) as the viral entry inhibitory agents to block the attachment of gp120 from the viral envelope and CD4 receptor or coreceptor CCR5 from host cells, thereby preventing HIV infection [42]. Their project was prepared by using pyrolyzed-citric acid (CA) method to exhibit a graphene-like structure of CQDs with abundant functional groups (-OH, -COOH) on their surfaces. To create the inhibitory efficiency, the prepared CQDs were conjugated with carboxyl phenylboronic acid (CBBA), thereby blocking the viral entry. Comparatively, the antiviral activity-evaluated assay of the modified CBBA carbon dots (CBBA-CQDs) behaved more synergistically to prohibit HIV infection than the prepared carbon dots alone. In regard to their cytotoxicity assessments, the average percentage of cell viability at different concentrations was higher than 80%, ascribing both CQDs and modified CQDs are non-toxic in human cells. Thus, their findings highlighted that the intrinsically antiviral property of carbon dot-based applications would further be able to use in HIV prevention and treatment [42]. Therefore, it can be said that the preparation of carbon based-materials and their properties are worth to use in multiple fields including antiviral blocking systems for human-effective surroundings.

Carbon Quantum Dots for Viral Theranostics

Carbon dots (CDs) or carbon-based quantum dots (CQDs) are the typical form of semiconductor nanocrystals with promising small dimensions as mentioned above. They intrinsically display optical properties, for example, photostability, high absorbance cross-section, comparatively long lifetime of stable fluorescence, and high quantum yield of around 70 to 80% [166]. The tuneable colour of CQDs fluorescence with respect to the emission wavelength would be varied from 450 to 1800 nm by administrating their size, structure, and framework of the nanocrystals. Their broad-excitation spectrum and narrow-emission spectrum can boost the tendency of numerous selected molecules *in vivo* or *in vitro* probes [167]. Since the carbon quantum dots have been increasingly researched in the field of antiviral applications, novel CQDs have been developed with good biocompatibility and antiviral activity. Currently, promising CQDs were prepared by the hydrothermal treatment and modified with

functionalization to their surface sites in order to exhibit potent antiviral activity [168, 169, 170]. However, the detailed procedures of the antiviral activity of these CQDs still need to be further clarified, and also the cellular response to them is unrevealed [34].

Ju *et al.* 2020 have prepared the carbon quantum dots combining poly (ethylenimine) and citric acid using microwave-assisted pyrolysis and the as-prepared CQDs were conjugated with locked nucleic acid (LNA) as shown on Fig 1 [171]. It was found that the inhibitory effects of viral miRNAs by green carbon quantum dots-interposed delivery of locked nucleic acid (CQDs-LNA)-base inhibitors suppress the reproduction of KSHV (Kaposi's sarcoma-associated herpesvirus)-related initial effusion lymphoma (PEL) cells [171].




Fig. 1: The graphical abstract design of viral microRNAs inhibition by carbon quantum dots-interposed drug-loading of locked nucleic acids (CQDs-LNA) for viral therapy. The image is reproduced with the permission from reference [171].

Tong *et al.* 2020 [172], reported the glycyrrhizin acid-based carbon dots (Gly-CDs) prepared from Chinese herbal medicine by a hydrothermal treatment. The result showed that Gly-CDs can inhibit the porcine propagation and respiratory syndrome virus (PPRSV) invasion and reproduction, stimulating antiviral innate immune systems. The cell viability of both Vero cells and PK-cells makes them possible to use in biomedical fields because the mean percentage of their proliferation rate is above 80% (Fig 2a). They also inhibited the aggregation of intracellular reactive oxygen species (ROS) affected by PRRSV infection as indicated in Fig 2b, attributing a potential agent for alternative theranostics of PRRSV contagion [172].




Fig. 2: (a) The broad-spectrum antiviral efficiency of Gly-CDs. The incubation of both Vero and PK-15 cells individually with Gly-CDs at different concentrations of 0.15, 0.30, 0.60, and 0.90 mg mL⁻¹ for 12 and 24 h. (b) Cellular ROS levels in PRRSV (porcine propagation and respiratory syndrome virus)-infected MARC-145 cells post different treatments. The cell group showed normal cells with no contact by both Gly-CDs and PRRSV. The mock group exhibited the PRRSV-infected cells in the absence of Gly-CDs treatment. Gly-CDs group indicated the PRRSV-infected cells medicated with Gly-CDs. Scale bar = 100 μm. The images are reprinted with the permission from reference [172].

Another study reported by Huang *et al*is the outstanding CQDs synthesized from a series of benzoxazine monomer (BZM-CQDs) and showed their virus-blocking activity in case of death-dealing flaviviruses (Japanese encephalitis, dengue viruses, and Zika) and a kind of non-enveloped viruses (porcine parvovirus and adenovirus-correlated virus) in vitro (as showed on Fig 3)[168]. They found that BZM-CDs could immediately adhere to the virion surface, and finally, the initiative of virus-cell interconnection was destroyed and it was believed

that the BZM-CDs could contribute to a fascinating broad-spectrum technique to suppress viral infections [168].

Hence, the carbon-based quantum dots or graphene quantum dots are one of the potential and efficient platforms for viral therapeutics and they would also be alternative antiviral prevention and treatment agents for HIV in the future, upgrading a new and upcoming development of nanomedicine with huge potential in the field of viral theranostics




Fig. 3: The graphical abstract framework of prepared BZM-Carbon dots to block viral infectivity. The image is reproduced with the permission from reference [168].




Fig. 4: (a) The schematic diagram of the one-step synthesis of Cur-CQDs [173], (b) their abstract framework of the antiviral application system, and (c) The RTIs (reverse transcriptase inhibitors)-conjugated compound GQDs as a promising candidate for HIV treatment [31]. The images are reprinted with the permission from represented references.

Carbon Quantum Dots' Antiviral Functions

The modified CQDs have been recently recognized as a cost-effective therapeutic strategy to exert a modifying or controlling influence on viral attachment and entry. The highly-concentrated and propagated ligands existed on the surface of

nanostructures can noticeably improve affinities toward multiple biological receptors [41, 174].

Virus-cell interactions primarily include the event that the viruses firstly attach and adsorb to biological receptors of the host cell, and then penetrated the cell and replicated. The viral envelope mediates the binding of HSV-1 to cells. Inhibiting this adsorption mechanism is thus regarded as an effective system to prevent the infection to the cell [175]. Some carbon sources of natural products (curcumin, flavonoids, polyphenol compounds) showed their intrinsic antiviral, antioxidant, anticancer, anti-inflammatory, and antibacterial functions [173]. Ali *et al.* claimed that curcumin prevents HIV-1 contagion from degrading Tat protein and decreasing the Tat-interposed transcription of the toll-like receptor (TLR) promoter [176]. Since they are poorly water-insoluble in physiological media and low bioavailability in vivo system, the direct usage of the pure natural products to cell lines is limited. Thus, it requires using the sustainable, safe, and effective alternative like natural products transformation into CQDs are required to enhance solubility, bioavailability, and antiviral and cancer staining mode of action as well [177, 178]. Like those sustainable nano-based antiviral agents, scientific researchers have investigated so far as potential alternatives to treat viruses or diseases due to their unique biological properties, morphological characteristics (e.g. controllable size, structure), and physicochemical characteristics, which significantly differs from those of conventional small-molecule dyes or drugs. Among different nano-based materials, silver nanoparticles (AgNPs) have considerably received the commercial interest due to their higher intrinsic virtues and several investigations have approved that AgNPs have strong antiviral activities against multiple viruses, for example, human immunodeficiency virus (HIV), H₁N₁ influenza virus, herpes simplex virus (HSV) and so on [179].

However, silver/ gold nanoparticles are not guaranteed regarding the cytotoxic safety to human cells and there are being evaluated before the use of those metal-based nanoparticles to theranostics enhancement, in case that the underlying long-term sequelae would be affected after post-treatment [70, 180]. Therefore, nano-antibiotics based on non-metallic nanoparticles or sustainable nanomaterials have widely drawn great interest owing to their solubility, safety, bioavailability, and synergistic antiviral effect. Both the promising investigations of semiconductor CQDs and sustainable or green carbon quantum dots for the antiviral activity were tabulated on Table-4.

Table-4: Carbon Quantum Dots Developed For Antiviral Activity.

Source or Name of CQDs	Bioconjugated Agents/Method	Characteristics (Size, Morphology, Toxicity, and IC ₅₀)	Cells/Virus	Purpose	References
PBA-CQDs 3-APBA-CQDs 4-APBA-CQDs	Hydrothermal carbonization	•Size diameters = 332±60 nm, 55 ± 1nm, 96 ± 1nm, respectively •Zeta potential = -27.0 ± 6mV, -37±1mV, -41± 1mV, respectively •Cell viability = 67%, 95%, 97% •IC ₅₀ = 80 and 145 ng/mL	•A549 Cells & Vero Cells/ •HSV-1	•To block viral attachment and entry.	[41]
CCM-CQDs	Citric acid/ A simple one-step pyrolysis method	•Particle sizes = 1.5 ± 0.3 nm, and zeta potential is 15.6 ± 2.05 mV. •Cell viability = 90%	•Vero cells/ •Coronavirus	•To inhibit the viral entry •To prevent budding of negative-strand RNA in virus.	[181]
Young barley leaves' powders B-CQDs	Citric acid/ Hydrothermal treatment	•Average diameter in size = 1.9 nm •Cell viability = over 85%	•Hela cells & PK-15 cells/ •Pseudorabies virus (PRV)	•To evaluate bioimaging and antiviral activities	[170]
Citric acid modified by boronic acid CQDs	Carboxyl phenylboronic acid (CBBA)/ Pyrolysis	•Diameter = 2.8 nm - 6.2 nm, zeta potential = 55.4 ± 8.2 •Cell viability = < 80% •IC ₅₀ = 9506.3 and 26.7 µg/mL •Mean size = 4.4 ± 0.6 nm •Cell viability = >80%	•MT4 and MOLT-4 cells/ •HIV-1	•To inhibit HIV infection	[42]
BZM-CQDs	Hydrothermal method	•Particle size = 33 nm •CC ₅₀ = 40.5 ± 6.5 •EC ₅₀ = 1.52 ± 0.18	•BHK-21 Cells & Vero cells/ •Flaviviruses	•To block the viral infection	[168]
Curcumin	Apotransferrin NPs (Nano-curcumin) Sol-oil chemistry method	•Curcumin-loaded NP size = 55– 70 nm •GI ₅₀ = 32.5 mM •IC ₅₀ = 1.75 mM	•SUPT1 cells or stimulated PBMCs/ •HIV-1	•To inhibit HIV-1 propagation is targeted to viral cDNA synthesis.	[182]
Graphene oxide (GO)	-	•Particle size = 0.9 nm to 2.7 nm •Cell viability = <100%	•Neuroblastoma cells & T cells/ •HIV-1	•To reduce Virus protein R (Vpr)	[163]
AgNPs	Tannic acid	•Particle size = 6.5 ± 0.2 •EC ₅₀ = 52 ± 8 µg mL ⁻¹	•African green monkey kidney (GMK-AH1) cells / •HSV-1	•To suppress HSV-2 infectivity both <i>in vitro</i> and <i>in vivo</i>	[183]
Ethylenediamine + citric acid (CQDs)	Boronic acid/ Hydrothermal carbonization	•Particle size = 4 – 5nm	•Huh-7 cells/ •HCoV	•To inhibit viral replication.	[174]
Citric acid and ethylene diamine (CQDs)	Streptavidin/ Hydrothermal thermal treatment	•Mean diameters = 4.8 ± 0.8 •CC ₅₀ = 452.2 µg mL ⁻¹ •EC ₅₀ = 0.2 µg mL ⁻¹	•HIV-1	•To determine HIV-1 p24 antigen on developed Whatman filter paper and nitrocellulose paper	[184]
Cur-CQDs	Pyrolysis	•Mean size = 157 ± 8.9 •Zeta potential = +2.4 ± 0.3	•RD cells/ •EV71	•To inhibit EV71 infection	[173]
Ritonavir-loaded NPs	Conjugated with TAT-peptide An emulsion-solvent evaporation technique		•MDCK-MDR1 and MDCK-wt cells -	•To deliver the TAT-conjugated NPs in the CNS to inhibit replicating HIV-1 virus	[185]

Abbreviation: PBA, 4-phenylboronic acid; 3-APBA, 3-aminophenylboronic acid; 4-APBA, 4-aminophenylboronic acid hydrochloride; PBMCs, peripheral blood mononuclear cells; CCM-CQDs, cationic curcumin-based carbon quantum dots; BZM-CQDs, benzoxamine-based carbon quantum dots; Cur-CQDs, curcumin-based carbon quantum dots.

The collected articles have proven the satisfactory efficiency of carbon dots-based antiviral agents derived from molecules, compounds, combining complex nano-substances. Also, some of promising articles representing the antiviral activity of facile prepared-carbon dots with surface modification or conjugation are explained. The above-mentioned published research mostly

explained the viral inhibition, and thus the cycle of virus affected by the antiviral activity from carbon-based dots nanomaterials. Therefore, there would be deduced from the above results, it is specifically clarified that carbon dots-based antiviral agents from curcumin-based carbon dots exhibited great ability against RNA viruses. Moreover, it is noticeable that surface modification or functionalization also

enhanced the efficiency of carbon dots antiviral agents.

Nano-Vaccines in HIV Prevention

To reduce infectious disease transmission, appropriate methods are required, depending on the nature of the disease and mode of action of transmission. For example, vaccination is required for some diseases, which completely inhibits the illness such as polio and measles [29]. Hence, both prophylactic and therapeutic systems have been applied by nanovaccinology. They can make it possible to enhance the bodily immune response to antigen mode of action or used as an immunostimulatory adjuvant [186]. A prophylactic HIV vaccine is normally regarded as the anticipating one to suspend the movement of the AIDS pandemic; but the improvement of the simple, safe, and efficient HIV-1 vaccine is still in unknown condition [187]. Recently, there has been studied in Thailand to assess a prime-boost regimen of ALVAC HIV, and this canarypox virus vector can help HIV *env*, *gag*, and *pro* genes express, thereby stimulating with AIDSVAX, a recombinant envelope gp120 protein. Eventually, great efficacy was partially exhibited in inhibiting accretion of HIV. Despite good results of this investigation for vaccinology development in the future, new concepts remain to be further approved [188, 189].

The advantages of prophylactic HIV-1 vaccination preparation by using nanoparticles involve safety description provided by the usefulness of biocompatible biomaterials as well as vaccine dose titration; prohibition of HIV-1 antigens from being degradable enzyme dynamics, in this way, enhancing the *in vivo* stability of immunogens and their interactions with antigen-presenting cells (APCs) [190]. And hence, the targeting to APC-enriched lymphoid tissues, the phagocytosis, and the processing of HIV-1 antigens would be improved. Moreover, the smaller sizes of the nanoparticles are considered as one of the vaccine-delivery benefits because these used nanoparticles are as small as expressing viruses and bacteria which are easily identified by the immune system [191].

There are urgently two important issues to develop the HIV vaccine methodology, namely: innovating design and producing immunogens. The very effective immunogen design has hardly confirmed because of various evasion pathways and the lifecycle of HIV. Within each HIV subtype, the amino acid series of the envelope glycoprotein (Env),

which occupies the virion surface, change from 4 to 30%, while the amino acid sequences from the HIV subtype to subtype can vary from 20 to 36% [188].

The promising vaccine studies associating with nanotechnology are described as follows. The most suited and recent improvements in the vaccine delivery technologies for HIV vaccination including nanocarrier-based strategies are

- (1) Live vaccine vectors for vaccination against HIV-1,
- (2) Next-generation HIV-1 immunogens for eliciting bNAbs responses,
- (3) Self-assembling 'virus-like' nanoparticles for the presentation of HIV-1 antigens, and
- (4) siRNA-based nanotherapeutics to inhibit HIV-1 infection [188, 192].

Despite the successful developments of many vaccines against polio, measles, mumps, rubella, and yellow fever worldwide, the performance of this innovative approach does not suit for HIV-1 because of its virulence and high mutation rate. As a first alternative strategy, live-vector-based vaccines use genetically weak pathogens to exert viral antigens, vitalizing the host immune system. Benlahrech et al. 2009 have reported that among vaccines with pre-existing immunity to Ad5, vaccination enhanced activation of Ad5-specific memory T cells and their consequent trafficking to mucosal tissues, thus accidentally facilitating a high frequency of target CD4+ T cells at the local site of HIV-1 entry [193].

An additionally another point of the vaccine of HIV immunogens receives the optimal results from the RV144 Phase III trial. The trial proposed that the modest inhibition explored was from V1V2-specific antibodies, a region of HIV-1 gp120 involving unprotected surface areas regarded by bNAbs, such as PG9. While HIV-1 immunogens will require to be continuously improving and exploring, their vaccine delivery systems will make sure to enhance the immunity, inhibiting the immunogen in the absence of obstructing the key epitopes [194].

Moreover, self-assembling into nanoparticles imitates virus-like particles for the multivalent exhibition of Env-based immunogens, including germline targeting gp120 outer domains, Clade C ZM109-based V1V2 domain trimers, BG505 gp120 trimers, and BG505-SOSIP gp140 modelled trimers [195].

Contrary to self-assembling “virus-like” nanoparticles, synthetic polymer-based nanoparticles, and liposome-based nanovesicles provide adaptable acting technologies that can influence strong versatile immune responses while keeping away from antivectorial immunity and toxicity problems. For example, polymeric nanoparticles relied on biodegradable and biocompatible poly (lactic-co-glycolic) acid (PLGA) copolymer that has been widely investigated for vaccine delivery use. Kasturi *et al.* 2011 have smartly reported that PLGA nanoparticles co-loaded with TLR4 and TLR7/8 agonists can co-actively standardize the inauguration of antigen-specific antibody responses in nonhuman primates (NHPs) via activating germinal center and plasma cell responses in lymphoid tissues. These findings provided the adaptability of PLGA particle methods for the fast-loading mode of peptide antigens and adjuvants. The designing framework and synthetic method of polymeric particle vaccines have been elegantly advanced above, there remains a lot of challenges to obtain a suited multivalent presentation of complex immunogens, such as Env trimers, in their native composition from polymeric particles [196].

Another alternative HIV-1 vaccine strategy is siRNA-based nanotherapeutics, compressing CD4, and co-receptor CCR5 [197]. Kim *et al.* 2010 have prepared the development of liposomes decorated with antibodies against LFA-1, an integrin site on leukocytes. Those LFA-1-targeted liposomes conveyed siRNA against CCR5, bringing about a significant reduction in CCR5 mRNA levels among leukocytes for 10 days, which would label the transient effect of siRNA-based therapeutics and control long-term immunity against HIV-1 [1].

Conclusion

In summary, highly active anti-retroviral theranostics, nano-theranostics, carbon quantum dots-based theranostics, and nano-vaccine therapy approaches for HIV or other viruses have been presented systemically in this review. Those approaches have had promising or advantageous effects on virus inhibition and treatment, whereas a few drawbacks have been challenging.

Due to the deadly multiple viruses, especially HIV/AIDS infection to human societies around the world especially to the developing countries as pandemic levels, scientific researchers have approached to explore new strategic prevention and treatments to eradicate those diseases. Various forms of nanocarriers (efficient drug-loading

capability) have been needed to increase the potential delivery of antiretroviral drugs for HIV remedy so that the complicated issues of both the HIV infection cycle and the targets for delivery of drugs could be overcome. Meanwhile, scientific researchers have been looking for new ways to find the novelty of promising results. In regard to promising drug delivery systems, nano-based polymeric or inorganic materials play a significant role in numerous models ranging from *in vitro* to *in vivo* as nanocarriers.

Moreover, carbon-based nanomaterials, carbon quantum dots are also promising for HIV prevention and treatment. However, coating with different types of ligands is to better inhibit viruses [174]. Also, CQDs could significantly improve the merits of targeting and long-lasting mode of action only when their surface sites get modified with selected functional groups for better surface modification [198]. To be as low as toxic, green or sustainable carbon nanodots, intrinsic antiviral properties are also necessary for nano-delivery systems to increase the drug's capability and reduce the side effects.

As the nano-vaccine aspect, to further develop nanotechnology-based vaccines might require to keep targeting on the immunologic description of antigens preservation, immune cells of interest, and the system of administration optimization so as to fabricate a successful vaccine.

Taken all together, to have good patient adherence to treatment or excellent aqueous solubility, to achieve safe and better drug delivery nanocarriers, to obtain the high antiviral mode of action response, and to get a successful HIV-1 vaccine expanding immunogen arsenal are still demanded to pursue consistent clinical improvements for patients.

Conflict of interest

The authors declare no conflict of interest in the present study.

Acknowledgement

The authors thank Ministry of Research and Technology, Republic of Indonesia and Universitas Airlangga for any supports in the present study.

References

1. P. S. Kim and S. W. Read, Nanotechnology and HIV: potential applications for treatment and

- prevention. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., **2**, 693 (2010).
2. T. Mamo, E. A. Moseman, N. Kolishetti, C. Salvador-Morales, J. Shi, D. R. Kuritzkes, R. Langer, U. v. Andrian and O. C. Farokhzad, Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. *Nanomedicine*, **5**, 269(2010).
 3. G. A. Mansoori and T. F. Soelaiman, Nanotechnology—an introduction for the standards community. *J. ASTM Int.*, **2**, 1 (2005).
 4. P. Boisseau and B. Loubaton, Nanomedicine, nanotechnology in medicine. *C R Phys.*, **12**, 620 (2011).
 5. D. Seth, A. Sarkar and D. Mitra, Nanomedicine to counter syndemic tuberculosis and HIV infection: Current knowledge and state of art. *Nanosci. Nanotechnol.*, **2**, 1 (2014).
 6. S. D. Mahajan, R. Aalinkeel, W. C. Law, J. L. Reynolds, B. B. Nair, D. E. Sykes, K.-T. Yong, I. Roy, P. N. Prasad and S. A. Schwartz, Anti-HIV-1 nanotherapeutics: promises and challenges for the future. *Int. J. Nanomed.*, **7**, 5301 (2012).
 7. A. Kumar, H. Ma, X. Zhang, K. Huang, S. Jin, J. Liu, T. Wei, W. Cao, G. Zou and X. J. Liang, Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. *Biomaterials*, **33**, 1180 (2012).
 8. S. E. McNeil, *Unique Benefits of Nanotechnology to Drug Delivery and Diagnostics*. In: McNeil S. (eds) *Characterization of Nanoparticles Intended for Drug Delivery. Methods in Molecular Biology (Methods and Protocols)*, Humana Press, New Jersey, p. 3 (2011).
 9. L. Singh, H. G. Kruger, G. E. Maguire, T. Govender and R. Parboosing, The role of nanotechnology in the treatment of viral infections. *Ther. Adv. Infect. Dis.*, **4**, 105 (2017).
 10. R. W. Y. Sun, R. Chen, N. P. Y. Chung, C. M. Ho, C. L. S. Lin and C. M. Che, Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. *Chem. comm.*, **40**, 5059 (2005).
 11. M. Gagliardi, Biomimetic and bioinspired nanoparticles for targeted drug delivery. *Ther. deliv.*, **8**, 289 (2017).
 12. M. C. Bowman, T. E. Ballard, C. J. Ackerson, D. L. Feldheim, D. M. Margolis and C. Melander, Inhibition of HIV fusion with multivalent gold nanoparticles, *J. Am. Chem. Soc.*, **130**, 6896 (2008).
 13. M. J. Santos-Martinez, K. Rahme, J. J. Corbalan, C. Faulkner, J. D. Holmes, L. Tajber, C. Medina and M. W. Radomski, Pegylation increases platelet biocompatibility of gold nanoparticles. *J. biomed. nanotechnol.*, **10**, 1004 (2014).
 14. L. Zhang, F. Gu, J. Chan, A. Wang, R. Langer and O. Farokhzad, *Clinical Pharmacol. Ther.*, **83**, 761 (2008).
 15. J. Lisziewicz, D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz and R. C. Gallo, Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. *Proc. Natl. Acad. Sci. U S A.*, **90**, 8000 (1993).
 16. N. L. Letvin and B. D. Walker, Immunopathogenesis and immunotherapy in AIDS virus infections. *Nat. Med.*, **9**, 861 (2003).
 17. C. L. Parks, L. J. Picker and C. R. King, Development of replication-competent viral vectors for HIV vaccine delivery. *Curr. Opin. HIV AIDS.*, **8**, 402 (2013).
 18. N. M. Khalil, E. Carraro, L. F. Cótica and R. M. Mainardes, Potential of polymeric nanoparticles in AIDS treatment and prevention. *Expert Opin Drug Deliv.*, **8**, 95 (2011).
 19. D. D. Danilo, *Liposomes from physics to applications*. Handbook of Biological Physics, Elsevier, p. 63 (1993).
 20. J. L. Jimenez, M. Pion, F. J. de la Mata, R. Gomez, E. Munoz, M. Leal and M. A. Muñoz-Fernandez, Dendrimers as topical microbicides with activity against HIV. *New J. Chem.*, **36**, 299 (2012).
 21. P. Shah, D. Bhalodia and P. Shelat, Nanoemulsion: a pharmaceutical review. *Syst. Rev. Pharm.*, **1**, 1 (2010).
 22. R. Shegokar, M. Jansch, K. K. Singh and R. H. Müller, In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. *Nanomed-Nanotechnol. Bio. and Med.*, **7**, 333 (2011).
 23. M. Rai, A. P. Ingle, I. Gupta and A. Brandelli, Bioactivity of noble metal nanoparticles decorated with biopolymers and their application in drug delivery. *Int. J. Pharm.*, **496**, 159 (2015).
 24. P. Sharma and S. Garg, Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. *Adv. Drug Deliv. Rev.*, **62**, 491 (2010).
 25. L. Zhou, J. Huang, B. Yu, Y. Liu and T. You, A novel electrochemiluminescence immunosensor

- for the analysis of HIV-1 p24 antigen based on P-RGO@ Au@ Ru-SiO₂ composite. *ACS Appl. Mater. Interfaces.*, **7**, 24438 (2015).
26. V. Chukkapalli, S. J. Oh and A. Ono, Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. *Proc. Natl. Acad. Sci. U S A.*, **107**, 1600 (2010).
 27. H. Budka, Human immunodeficiency virus (HIV) envelope and core proteins in CNS tissues of patients with the acquired immune deficiency syndrome (AIDS). *Acta neuropathol.*, **79**, 611 (1990).
 28. J. Liu, S. Dai, M. Wang, Z. Hu, H. Wang and F. Deng, Virus like particle-based vaccines against emerging infectious disease viruses. *Virol. Sin.*, **31**, 279 (2016).
 29. W. Muhammad, Z. Zhai and C. Gao, Antiviral Activity of Nanomaterials against Coronaviruses. *Macromolecular bioscience.*, **20**, 2000196 (2020).
 30. M. A. Macchione, C. Guerrero-Beltrán, A. P. Rosso, E. M. Euti, M. Martinelli, M. C. Strumia and M. Á. Muñoz-Fernández, Poly (N-vinylcaprolactam) Nanogels with Antiviral Behavior against HIV-1 *Infection.Sci. Rep.*, **9**, 1 (2019).
 31. D. Iannazzo, A. Pistone, S. Ferro, L. De Luca, A. M. Monforte, R. Romeo, M. R. Buemi and C. Pannecouque, Graphene quantum dots based systems as HIV inhibitors. *Bioconjug. Chem.*, **29**, 3084 (2018).
 32. R. Wang, K.-Q. Lu, Z.-R. Tang and Y.-J. Xu, Recent progress in carbon quantum dots: synthesis, properties and applications in photocatalysis., *J. Mater. Chem.A.*, **5**, 3717 (2017).
 33. Y. Wang and A. Hu, Carbon quantum dots: synthesis, properties and applications. *J. Mater. Chem. C.*, **2**, 6921 (2014).
 34. T. Tong, H. Hu, J. Zhou, S. Deng, X. Zhang, W. Tang, L. Fang, S. Xiao and J. Liang, Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms. *Small*, **16**, 1906206 (2020).
 35. N. Puvvada, B. P. Kumar, S. Konar, H. Kalita, M. Mandal and A. Pathak, Synthesis of biocompatible multicolor luminescent carbon dots for bioimaging applications. *Sci. Technol. Adv. Mater.*, **13**, 045008 (2012).
 36. Y. Yu, C. Li, C. Chen, H. Huang, C. Liang, Y. Lou, X.-B. Chen, Z. Shi and S. Feng, Saccharomyces-derived carbon dots for biosensing pH and vitamin B 12. *Talanta*, **195**, 117(2019).
 37. R. M. Shereema, V. Sankar, K. Raghu, T. P. Rao and S. S. Shankar, One step green synthesis of carbon quantum dots and its application towards the bioelectroanalytical and biolabeling studies. *Electrochim. Acta.*, **182**, 588 (2015).
 38. H. He, X. Zheng, S. Liu, M. Zheng, Z. Xie, Y. Wang, M. Yu and X. Shuai, Diketopyrrolopyrrole-based carbon dots for photodynamic therapy. *Nanoscale.*, **10**, 10991 (2018).
 39. M. Z. Fahmi and J.-Y. Chang, A facile strategy to enable nanoparticles for simultaneous phase transfer, folate receptor targeting, and cisplatin delivery. *RSC Adv.*, **4**, 56713 (2014).
 40. T. Du, J. Liang, N. Dong, L. Liu, L. Fang, S. Xiao and H. Han, Carbon dots as inhibitors of virus by activation of type I interferon response. *Carbon.*, **110**, 278 (2016).
 41. A. Barras, Q. Pagneux, F. Sane, Q. Wang, R. Boukherroub, D. Hober and S. Szunerits, High efficiency of functional carbon nanodots as entry inhibitors of herpes simplex virus type 1. *ACS Appl. Mater. Interfaces.*, **8**, 9004 (2016).
 42. M. Fahmi, W. Sukmayani, S. Q. Khairunisa, A. Witaningrum, D. Indriati, M. Matondang, J. Y. Chang, T. Kotaki and M. Kameoka, Design of boronic acid-attributed carbon dots on inhibits HIV-1 entry. *RSC advances.*, **6**, 92996 (2016).
 43. F. D. Cojocar, D. Botezat, I. Gardikiotis, C. M. Uritu, G. Dodi, L. Trandafir, C. Rezus, E. Rezus, B. I. Tamba and C. T. Mihai, Nanomaterials designed for antiviral drug delivery transport across biological barriers. *Pharmaceutics*, **12**, 171 (2020).
 44. P. Curley, N. J. Liptrott and A. Owen, Advances in nanomedicine drug delivery applications for HIV therapy. *Future Sci.*, **4**, FSO230 (2017).
 45. A. A. Date and C. J. Destache, A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. *Biomaterials.*, **34**, 6202 (2013);
 46. U. Gupta and N. K. Jain, Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. *Adv. Drug Deliv. Rev.*, **62**, 478 (2010).
 47. D. Lembo and R. Cavalli, Nanoparticulate delivery systems for antiviral drugs. *Antivir. Chem. Chemother.*, **21**, 53 (2010).
 48. M. Monroe, C. Flexner and H. Cui, Harnessing nanostructured systems for improved treatment and prevention of HIV disease. *Bioeng. Transla. Med.*, **3**, 102 (2018).

49. A. Valizadeh, *Artificial cells*, Nanomaterials and optical diagnosis of HIV. *Artif. Cell. Nanomed. Biotechnol.*, **44**, 1383 (2016).
50. B. Braveman, M. Levin, G. Kielhofner and M. Finlayson, HIV/AIDS and return to work: a literature review one-decade post-introduction of combination therapy (HAART). *Work.*, **27**, 295 (2006).
51. A. S. Muula, T. J. Ngulube, S. Siziya, C. M. Makupe, E. Umar, H. W. Prozesky, C. S. Wiysonge and R. H. Mataya, Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. *BMC public health.*, **7**, 63 (2007).
52. J. A. Joska, H. Gouse, R. H. Paul, D. J. Stein and A. J. Flisher, Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. *J. Neurovirology.*, **16**, 101 (2010).
53. C. M. Puskas, J. I. Forrest, S. Parashar, K. A. Salters, A. M. Cescon, A. Kaida, C. L. Miller, D. R. Bangsberg and R. S. Hogg, Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. *Curr. HIV/AIDS Rep.*, **8**, 277 (2011).
54. F. J. Piacenti, An update and review of antiretroviral therapy. *Pharmacother.- J. Hum. Pharm. Drug Ther.*, **26**, 1111 (2006).
55. M. O. Akanbi, K. Scarsi, B. Taiwo and R. L. Murphy, Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection. *Expert Opin. Pharmacother.*, **13**, 65 (2012).
56. I. Usach, V. Melis and J. E. Peris, Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. *J. Int. AIDS Soc.*, **16**, 18567 (2013).
57. A. Fun, A. M. Wensing, J. Verheyen and M. Nijhuis, Human Immunodeficiency Virus Gag and protease: partners in resistance. *Retrovirology.*, **9**, 63 (2012).
58. E. Thierry, E. Deprez and O. Delelis, Different pathways leading to integrase inhibitors resistance. *Front. microbiol.*, **7**, 2165 (2017).
59. C. G. Anastassopoulou, *Chemokine Receptors as Therapeutic Targets in HIV Infection. Immunodeficiency*, Intech press, Croatia, p. 115 (2012).
60. C. A. Didigu and R. W. Doms, Novel approaches to inhibit HIV entry. *Viruses.*, **4**, 309 (2012).
61. K. Maduray and R. Parboosing, Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections. *Biol. Trace Elem. Res.*, **1** (2020).
62. J. Jeevanandam, A. Barhoum, Y. S. Chan, A. Dufresne and M. K. Danquah, Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. *Beilstein J. Nanotechnol.*, **9**, 1050 (2018).
63. A. Ali, M. Z. Hira Zafar, I. ul Haq, A. R. Phull, J. S. Ali and A. Hussain, Synthesis, characterization, applications, and challenges of iron oxide nanoparticles. *Nanotechnol. Sci. Appl.*, **9**, 49 (2016).
64. J. Wallyn, N. Anton and T. F. Vandamme, Synthesis, Principles, and Properties of Magnetite Nanoparticles for In Vivo Imaging Applications—A Review. *Pharmaceutics.*, **11**, 601 (2019).
65. J. J. Giner-Casares, M. Henriksen-Lacey, M. Coronado-Puchau and L. M. Liz-Marzán, Inorganic nanoparticles for biomedicine: where materials scientists meet medical research. *Mater. Today.*, **19**, 19 (2016).
66. D. Lombardo, M. A. Kiselev and M. T. Caccamo, Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. *J. Nanomater.*, **2019** (2019).
67. S. Galdiero, A. Falanga, M. Vitiello, M. Cantisani, V. Marra and M. Galdiero, Silver nanoparticles as potential antiviral agents. *Molecules*, **16**, 8894 (2011).
68. D. Chenthamara, S. Subramaniam, S. G. Ramakrishnan, S. Krishnaswamy, M. M. Essa, F. H. Lin and M. W. Qoronfleh, Therapeutic efficacy of nanoparticles and routes of administration. *Biomater. Res.*, **23**, 1 (2019).
69. H. H. Lara, N. V. Ayala-Nuñez, L. Ixtepan-Turrent and C. Rodriguez-Padilla, Mode of antiviral action of silver nanoparticles against HIV-1. *J. Nanobiotechnol.*, **8**, 1 (2010).
70. N. Khandelwal, G. Kaur, N. Kumar and A. Tiwari, Application of Silver Nanoparticles in Viral Inhibition: A New Hope for Antivirals. *Dig. J. Nanomater. Bios.*, **9**, 175 (2014).
71. I. Schick, S. Lorenz, D. Gehrig, S. Tenzer, W. Storck, K. Fischer, D. Strand, F. Laquai and W. Tremel, Inorganic Janus particles for biomedical applications. *Beilstein J. Nanotechnol.*, **5**, 2346 (2014).
72. M. Z. Fahmi and J. Y. Chang, Forming double layer-encapsulated quantum dots for bio-imaging and cell targeting. *Nanoscale*, **5**, 1517 (2013).
73. M. Z. Fahmi and J. Y. Chang, Potential application of oleylamine-encapsulated

- AgInS₂-ZnS quantum dots for cancer cell labeling. *Procedia Chem.*, **18**, 112 (2016).
74. W. M. Girma, M. Z. Fahmi, A. Permadi, M. A. Abate and J. Y. Chang, Synthetic strategies and biomedical applications of I–III–VI ternary quantum dots. *J. Mater. Chem. B.*, **5** (31), 6193 (2017).
75. J. G. Walter, S. Petersen, F. Stahl, T. Scheper and S. Barcikowski, Laser ablation-based one-step generation and bio-functionalization of gold nanoparticles conjugated with aptamers. *J. nanobiotechnol.*, **8**, 21 (2010).
76. M. Fatima, N. U. S. S. Zaidi, D. Amraiz and F. Afzal, In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza A virus. *J. Microbiol. Biotechnol.*, **26**, 151 (2016).
77. T. Q. Huy, N. T. H. Thanh, N. T. Thuy, P. Van Chung, P. N. Hung, A. T. Le and N. T. H. Hanh, Cytotoxicity and antiviral activity of electrochemical-synthesized silver nanoparticles against poliovirus. *J. Virol. Methods.*, **241**, 52 (2017).
78. J. L. Castro-Mayorga, W. Randazzo, M. J. Fabra, J. Lagaron, R. Aznar and G. Sánchez, Antiviral properties of silver nanoparticles against norovirus surrogates and their efficacy in coated polyhydroxyalkanoates systems. *LWT-Food Sci. Technol.*, **79**, 503 (2017).
79. R. Pangestika and R. Ernawati, Antiviral activity effect of silver nanoparticles (AgNPs) solution against the growth of infectious bursal disease virus on embryonated chicken eggs with Elisa test. *KnE life sci.*, **3**, 536 (2017).
80. A. Rónavári, D. Kovács, N. Igaz, C. Vágvölgyi, I. M. Boros, Z. Kónya, I. Pfeiffer and M. Kiricsi, Biological activity of green-synthesized silver nanoparticles depends on the applied natural extracts: a comprehensive study. *Int. J. Nanomed.*, **12**, 871 (2017).
81. L. Lu, R. Sun, R. Chen, C. K. Hui, C. M. Ho, J. M. Luk, G. Lau and C. M. Che, Silver nanoparticles inhibit hepatitis B virus replication. *Antiviral therapy.*, **13**, 253 (2008).
82. T. Du, J. Lu, L. Liu, N. Dong, L. Fang, S. Xiao and H. Han, Antiviral Activity of Graphene Oxide–Silver Nanocomposites by Preventing Viral Entry and Activation of the Antiviral Innate Immune Response. *ACS Appl. Bio Mater.*, **1**, 1286 (2018).
83. N. Mazurkova, Y. E. Spitsyna, N. Shikina, Z. Ismagilov, S. Zagrebelskiy and E. Ryabchikova, Interaction of titanium dioxide nanoparticles with influenza virus. *Nanotechnol. Russ.*, **5**, 417 (2010).
84. A. S. Levina, M. N. Repkova, V. F. Zarytova and N. A. Mazurkova, Presented at the 2015 *IEEE 15th International Conference on Nanotechnology (IEEE-NANO)* (2015).
85. D. Gerrity, H. Ryu, J. Crittenden and M. Abbaszadegan, Photocatalytic inactivation of viruses using titanium dioxide nanoparticles and low-pressure UV light. *J. Environ. Sci. Health A.*, **43**, 1261 (2008).
86. S. Vijayakumar and S. Ganesan, Gold nanoparticles as an HIV entry inhibitor. *Curr. HIV Res.*, **10**, 643 (2012).
87. S. Rafiei, S. E. Rezaatofghi, M. R. Ardakani and S. Rastegarzadeh, Gold nanoparticles impair foot-and-mouth disease virus replication. *IEEE Trans. Nanobiosci.*, **15**, 34 (2015).
88. S. R. Ahmed, J. Kim, T. Suzuki, J. Lee and E. Y. Park, Detection of influenza virus using peroxidase-mimic of gold nanoparticles. *Biotechnol. Bioeng.*, **113**, 2298 (2016).
89. Y. S. Chen, Y. C. Hung, W. H. Lin and G. S. Huang, Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. *Nanotechnol.*, **21**, 195101 (2010).
90. J. R. Carter, V. Balaraman, C. A. Kucharski, T. S. Fraser and M. J. Fraser, A novel dengue virus detection method that couples DNAzyme and gold nanoparticle approaches. *Virol. J.*, **10**, 201 (2013).
91. A. M. Paul, Y. Shi, D. Acharya, J. R. Douglas, A. Cooley, J. F. Anderson, F. Huang and F. Bai, Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. *J. Gen. Virol.*, **95**, 1712 (2014).
92. W. Tao, K. S. Ziemer and H. S. Gill, Gold nanoparticle–M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. *Nanomedicine.*, **9**, 237 (2014).
93. C. Wang, W. Zhu and B.-Z. Wang, Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro. *Antivir. Res.*, **12**, 4747 (2017).
94. Y. Liu, L. Zhang, W. Wei, H. Zhao, Z. Zhou, Y. Zhang and S. Liu, Colorimetric detection of influenza A virus using antibody-functionalized gold nanoparticles. *Analyst.*, **140** (12), 3989 (2015).
95. W. Tao, B. L. Hurst, A. K. Shakya, M. J. Uddin, R. S. Ingole, M. Hernandez-Sanabria, R. P. Arya, L. Bimler, S. Paust and E. B.

- Tarbet, Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses. *Antivir. Res.*, **141**, 62 (2017).
96. C. Wang, W. Zhu, Y. Luo and B. Z. Wang, Gold nanoparticles conjugating recombinant influenza hemagglutinin trimers and flagellin enhanced mucosal cellular immunity. *Nanomedicine.*, **14**, 1349 (2018).
 97. D. Baram-Pinto, S. Shukla, A. Gedanken and R. Sarid, Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. *Small*, **6**, 1044 (2010).
 98. H. Zazo, C. I. Colino and J. M. Lanao, Current applications of nanoparticles in infectious diseases. *J. Control. Release.*, **224**, 86 (2016).
 99. G. Romero and S. E. Moya, Synthesis of organic nanoparticles. *Front. Nanosci.*, **4**, 115(2012).
 100. B. L. Banik, P. Fattahi and J. L. Brown, Polymeric nanoparticles: the future of nanomedicine. *Wiley Interdiscip. Rev. Nanomed.*, **8**, 271 (2016).
 101. A. Bolhassani, S. Javanzad, T. Saleh, M. Hashemi, M. R. Aghasadeghi and S. M. Sadat, Polymeric nanoparticles: potent vectors for vaccine delivery targeting cancer and infectious diseases. *Hum. Vaccines Immunother.*, **10**, 321 (2014).
 102. J. M. Chan, P. M. Valencia, L. Zhang, R. Langer and O. C. Farokhzad, Polymeric nanoparticles for drug delivery. *Cancer Nanotechnol.*, **1**, 163-175 (2010).
 103. N. A. Ocheke, P. O. Olorunfemi and N. C. Ngwuluka, Nanotechnology and drug delivery part 2: nanostructures for drug delivery. *Trop. J. Pharm. Res.*, **8**, (2009).
 104. M. P. de Oliveira, E. Garcion, N. Venisse, J.-P. Benoît, W. Couet and J.-C. Olivier, Tissue distribution of indinavir administered as solid lipid nanocapsule formulation in *mdr1a* (+/+) and *mdr1a* (-/-) CF-1 mice. *Pharm. Res.*, **22**, 1898 (2005).
 105. K. Letchford and H. Burt, A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. *Eur. J. Pharm. Biopharm.*, **65**, 259 (2007).
 106. P. Zeng, Y. Xu, C. Zeng, H. Ren and M. Peng, Chitosan-modified poly (d, l-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. *Int. J. Pharm.*, **415**, 259 (2011).
 107. M. Mohajer, B. Khameneh and M. Tafaghodi, Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin. *Iran. J. Basic Med. Sci.*, **17**, 722 (2014).
 108. A. J. Thorley and T. D. Tetley, New perspectives in nanomedicine. *Pharmacol. Ther.*, **140**, 176 (2013).
 109. N. Kuntworbe, N. Martini, J. Shaw and R. Al-Kassas, Malaria Intervention Policies and Pharmaceutical Nanotechnology as a Potential Tool for Malaria Management. *Drug Dev. Res.*, **73**, 167 (2012).
 110. M. Qasim, D.-J. Lim, H. Park and D. Na, Nanotechnology for diagnosis and treatment of infectious diseases. *J. Nanosci. Nanotechnol.*, **14**, 7374 (2014).
 111. Y. Perrie, A. R. Mohammed, D. J. Kirby, S. E. McNeil and V. W. Bramwell, Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. *Int. J. Pharm.*, **364**, 272 (2008).
 112. N. A. Hanafy, M. El-Kemary and S. Leporatti, Micelles structure development as a strategy to improve smart cancer therapy. *Cancers.*, **10**, 238 (2018).
 113. K. Madaan, S. Kumar, N. Poonia, V. Lather and D. Pandita, Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. *J. Pharm. Bioallied Sci.*, **6**, 139 (2014).
 114. B. Noriega-Luna, L. A. Godínez, F. J. Rodríguez, A. Rodríguez, G. Zaldívar-Lelo de Larrea, C. Sosa-Ferreira, R. Mercado-Curiel, J. Manríquez and E. Bustos, Applications of dendrimers in drug delivery agents, diagnosis, therapy, and detection. *J. Nanomater.*, **2014** (2014).
 115. L. Palmerston Mendes, J. Pan and V. P. Torchilin, Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. *Molecules*, **22**, 1401 (2017).
 116. U. S. Bagul, V. V. Pisal, N. V. Solanki and A. Karnavat, Current status of solid lipid nanoparticles: a review. *J. Bioequivalence Bioavailab.*, **3**, 2 (2018).
 117. A. Sathali, P. Ekambaram and K. Priyanka, Solid lipid nanoparticles: a review. *Sci. Rev. Chem. Comm.*, **2**, 80 (2012).
 118. T. Yadavalli, J. Ames, A. Agelidis, R. Suryawanshi, D. Jaishankar, J. Hopkins, N. Thakkar, L. Koujah and D. Shukla, Drug-encapsulated carbon (DECON): A novel platform for enhanced drug delivery. *Sci. Adv.*, **5**, eaax0780 (2019).

119. X. Yang, S. J. Shah, Z. Wang, V. Agrahari, D. Pal and A. K. Mitra, Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir. *Drug Deliv.*, **23**, 2399 (2016).
120. C.-M. J. Hu, Y.-T. Chen, Z.-S. Fang, W.-S. Chang and H.-W. Chen, Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection. *Int. J. Nanomed.*, **13**, 8579 (2018).
121. V. Mishra, S. Mahor, A. Rawat, P. N. Gupta, P. Dubey, K. Khatri and S. P. Vyas, Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. *J. Drug Target.*, **14**, 45 (2006).
122. E. E. Chiellini, F. Chiellini and R. Solaro, Bioerodible polymeric nanoparticles for targeted delivery of proteic drugs. *Nanosci. Nanotechnol.*, **6**, 3040 (2006).
123. A. A. Öztürk and G. Kırımlıoğlu, Preparation and in vitro of characterization lamivudine loaded nanoparticles prepared by acid or ester terminated PLGA for effective oral antiretroviral therapy. *J. Res. Pharm.*, **23**, 897-913 (2019).
124. V. Sankar, M. L. Keerthi and N. Parmar, Formation and In-vitro Evaluation of Zidovudine-Lamivudine Nanoparticles. *Indian J. Pharm. Educ.*, **46**, 192 (2012).
125. X. Tang, Y. Liang, X. Liu, S. Zhou, L. Liu, F. Zhang, C. Xie, S. Cai, J. Wei and Y. Zhu, PLGA-PEG nanoparticles coated with anti-CD45RO and loaded with HDAC plus protease inhibitors activate latent HIV and inhibit viral spread. *Nanoscale Res. Lett.*, **10**, 1 (2015).
126. D. N. Venkatesh, M. Baskaran, V. V. S. R. Karri, S. S. Mannemala, K. Radhakrishna and S. Goti, Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect. *Saudi Pharm. J.*, **23**, 667 (2015).
127. P. Kumar, Y. Lakshmi and A. Kondapi, An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile. *HIV med.*, **18**, 452 (2017).
128. G. Zhang, D. Guo, P. K. Dash, M. Araújo, J. L. Wiederin, N. A. Haverland, J. Knibbe-Hollinger, A. Martinez-Skinner, P. Ciborowski and V. S. Goodfellow, The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. *Nanomedicine.*, **12**, 109-122 (2016).
129. L. Fiandra, M. Colombo, S. Mazzucchelli, M. Truffi, B. Santini, R. Allevi, M. Nebuloni, A. Capetti, G. Rizzardini and D. Prosperi, Nanoformulation of antiretroviral drugs enhances their penetration across the blood brain barrier in mice. *Nanomedicine.*, **11**, 1387 (2015).
130. S. Pollock, R. A. Dwek, D. R. Burton and N. Zitzmann, N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. *AIDS*, **22**, 1961 (2008).
131. A. Shibata, E. McMullen, A. Pham, M. Belshan, B. Sanford, Y. Zhou, M. Goede, A. A. Date and C. J. Destache, Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. *AIDS Res. Hum. Retrovir.*, **29**, 746 (2013).
132. P. K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan and C. J. Destache, Pharmacokinetic and tissue distribution profile of long acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model. *Pharm. Res.*, **34**, 2749 (2017).
133. P. Kumar, Y. S. Lakshmi and A. K. Kondapi, Triple drug combination of zidovudine, efavirenz and lamivudine loaded lactoferrin nanoparticles: an effective nano first-line regimen for HIV therapy. *Pharm. Res.*, **34**, 257 (2017).
134. M. Donalisio, F. Leone, A. Civra, R. Spagnolo, O. Ozer, D. Lembo and R. Cavalli, Acyclovir-loaded chitosan nanospheres from nano-emulsion templating for the topical treatment of herpesviruses infections. *Pharmaceutics.*, **10**, 46 (2018).
135. G. V. Patel, V. B. Patel, A. Pathak and S. J. Rajput, Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. *Drug Dev. Ind. Pharm.*, **40**, 80 (2014).
136. S. Akhter, S. Talegaonkar, Z. I. Khan, G. K. Jain, R. K. Khar and F. J. Ahmad, Assessment of ocular pharmacokinetics and safety of Ganciclovir loaded nanoformulations. *J. Biomed. Nanotechnol.*, **7**, 144 (2011).
137. M. M. Raskin, I. Schlachet and A. Sosnik, Mucoadhesive nanogels by ionic crosslinking of chitosan-g-oligo (NiPAam) polymeric micelles as novel drug nanocarriers. *Nanomedicine.*, **11**, 217 (2016).
138. Y. Shen and J. Tu, Preparation and ocular pharmacokinetics of ganciclovir liposomes. *AAPS J.*, **9**, E371 (2007).
139. M. Feng, Q. Cai, H. Huang and P. Zhou, Liver targeting and anti-HBV activity of reconstituted

- HDL–acyclovir palmitate complex. *Eur. J. Pharm. Biopharm.*, **68**, 688 (2008).
140. S. I. Kim, D. Shin, H. Lee, B.-Y. Ahn, Y. Yoon and M. Kim, Targeted delivery of siRNA against hepatitis C virus by apolipoprotein AI-bound cationic liposomes. *J. Hepatol.*, **50**, 479(2009).
141. S.-S. Kim, D. Peer, P. Kumar, S. Subramanya, H. Wu, D. Asthana, K. Habiro, Y. G. Yang, N. Manjunath and M. Shimaoka, RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. *Mol. Ther.*, **18**, 370 (2010).
142. J.-F. Gagné, A. Désormeaux, S. Perron, M. J. Tremblay and M. G. Bergeron, Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. *Biochim. Biophys. Acta Biomembr.*, **1558**, 198 (2002).
143. D. Lauster, M. Glanz, M. Bardua, K. Ludwig, M. Hellmund, U. Hoffmann, A. Hamann, C. Böttcher, R. Haag and C. P. Hackenberger, Multivalent Peptide–Nanoparticle Conjugates for Influenza-Virus Inhibition. *Angew. Chem., Int. Ed. Engl.*, **56**, 5931 (2017).
144. R. A. Petros and J. M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications. *Nat. Rev. Drug Discov.*, **9**, 615 (2010).
145. M. Kovochich, M. D. Marsden and J. A. Zack, Activation of latent HIV using drug-loaded nanoparticles. *PLoS one.*, **6**, e18270. (2011).
146. J. Duan, J. P. Freeling, J. Koehn, C. Shu and R. J. Ho, Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. *J. Pharm. Sci.*, **103**, 2520 (2014).
147. J. P. Freeling, J. Koehn, C. Shu, J. Sun and R. J. Ho, Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. *AIDS Res. Hum. Retrovir.*, **3**, 107 (2015).
148. M. d'Amora and S. Giordani, Carbon Nanomaterials for Nanomedicine. *Smart Nano. Biomed.*, Elsevier, New Jersey, pp. 103-113 (2018)
149. X. Xu, R. Ray, Y. Gu, H. J. Ploehn, L. Gearheart, K. Raker and W. A. Scrivens, Electrophoretic analysis and purification of fluorescent single-walled carbon nanotube fragments. *J. Am. Chem. Soc.*, **126**, 12736 (2004).
150. Y.-P. Sun, B. Zhou, Y. Lin, W. Wang, K. S. Fernando, P. Pathak, M. J. Mezziani, B. A. Harruff, X. Wang and H. Wang, Quantum-sized carbon dots for bright and colorful photoluminescence. *J. Am. Chem. Soc.*, **128**, 7756 (2006).
151. M. L. Bhaisare, A. Talib, M. S. Khan, S. Pandey and H. F. Wu, Synthesis of fluorescent carbon dots via microwave carbonization of citric acid in presence of tetraoctylammonium ion, and their application to cellular bioimaging. *Microchim. Acta.*, **182**, 2173 (2015).
152. J. Xu, F. Zeng, H. Wu, C. Hu, C. Yu and S. Wu, Preparation of a Mitochondria-targeted and NO-Releasing Nanoplatfrom and its Enhanced Pro-Apoptotic Effect on Cancer Cells. *Small*, **10**, 3750 (2014).
153. M. J. Molaei, Carbon quantum dots and their biomedical and therapeutic applications: a review. *RSC adv.*, **9**, 6460 (2019).
154. C. Yu, T. Xuan, D. Yan, S. Lou, X. Hou, Y. Chen, J. Wang and H. Li, Sesame-derived ions co-doped fluorescent carbon nanoparticles for bio-imaging, sensing and patterning applications. *Sens. Actuators B Chem.* **253**, 900 (2017).
155. X. Deng, L. Mammen, H. J. Butt and D. Vollmer, Candle soot as a template for a transparent robust superamphiphobic coating. *Sci.*, **335**, 67 (2012).
156. M. Z. Fahmi, D. L. N. Wibowo, S. C. W. Sakti and H. V. Lee, Human serum albumin capsulated hydrophobic carbon nanodots as staining agent on HeLa tumor cell. *Mat. Chem. Phys.*, **239**, 122266 (2020).
157. Q. Zhao, Facile preparation of low cytotoxicity fluorescent carbon nanocrystals by electrooxidation of graphite. *Chem. Commun.*, **41**, 5116 (2008).
158. Y. F. Kang, Y. H. Li, Y. W. Fang, Y. Xu, X. M. Wei and X. B. Yin, Carbon quantum dots for zebrafish fluorescence imaging. *Sci. Rep.*, **5**, 1 (2015).
159. M. Z. Fahmi, J. K. Chen, C. C. Huang, Y. C. Ling and J. Y. Chang, Phenylboronic acid-modified magnetic nanoparticles as a platform for carbon dot conjugation and doxorubicin delivery. *J. Mater. Chem. B.*, **3**, 5532 (2015).
160. L. Tang, R. Ji, X. Li, G. Bai, C. P. Liu, J. Hao, J. Lin, H. Jiang, K. S. Teng and Z. Yang, Deep ultraviolet to near-infrared emission and photoresponse in layered N-doped graphene quantum dots. *ACS Nano.*, **8**, 6312 (2014).
161. J. Zhou, X. Shan, J. Ma, Y. Gu, Z. Qian, J. Chen and H. Feng, Facile synthesis of P-doped carbon quantum dots with highly efficient photoluminescence. *RSC Adv.*, **4**, 5465 (2014).
162. Y. Shi, C. Li, S. Liu, Z. Liu, J. Zhu, J. Yang and X. Hu, Facile synthesis of fluorescent carbon dots for determination of curcumin based on

- fluorescence resonance energy transfer. *RSC Adv.*, **5**, 64790 (2015).
163. M. Zhang, X. Mao, C. Wang, W. Zeng, C. Zhang, Z. Li, Y. Fang, Y. Yang, W. Liang and C. Wang, The effect of graphene oxide on conformation change, aggregation and cytotoxicity of HIV-1 regulatory protein (Vpr). *Biomaterials*, **34**, 1383 (2013).
164. Q. Wang, C. Zhang, G. Shen, H. Liu, H. Fu and D. Cui, Fluorescent carbon dots as an efficient siRNA nanocarrier for its interference therapy in gastric cancer cells. *J. nanobiotechnol.*, **12**, 58 (2014).
165. J. Ge, Q. Jia, W. Liu, L. Guo, Q. Liu, M. Lan, H. Zhang, X. Meng and P. Wang, Red-emissive carbon dots for fluorescent, photoacoustic, and thermal theranostics in living mice. *Adv. Mater.*, **27**, 4169 (2015).
166. X. T. Zheng, A. Ananthanarayanan, K. Q. Luo and P. Chen, Glowing graphene quantum dots and carbon dots: properties, syntheses, and biological applications. *Small*, **11**, 1620 (2015).
167. G. Xu, S. Mahajan, I. Roy and K. T. Yong, Theranostic quantum dots for crossing blood–brain barrier in vitro and providing therapy of HIV-associated encephalopathy. *Front. pharmacol.*, **4**, 140 (2013).
168. S. Huang, J. Gu, J. Ye, B. Fang, S. Wan, C. Wang, U. Ashraf, Q. Li, X. Wang and L. Shao, Benzoxazine monomer derived carbon dots as a broad-spectrum agent to block. *J. Colloid Interface Sci.*, **542**, 198 (2019).
169. M. R. Du, S. J. Chen, W. H. Duan, W. Q. Chen and H. W. Jing, Role of Multiwalled Carbon Nanotubes as Shear Reinforcing Nanopins in Quasi-Brittle Matrices. *ACS Appl. Nano Mater.*, **1**, 1731 (2018).
170. H. Liu, Y. Bai, Y. Zhou, C. Feng, L. Liu, L. Fang, J. Liang and S. Xiao, Blue and cyan fluorescent carbon dots: one-pot synthesis, selective cell imaging and their antiviral activity. *RSC adv.*, **7**, 28016 (2017).
171. E. Ju, T. Li, Z. Liu, S. R. da Silva, S. Wei, X. Zhang, X. Wang and S.-j. Gao, Specific Inhibition of Viral MicroRNAs by Carbon Dots-Mediated Delivery of Locked Nucleic Acids for Therapy of Virus-Induced Cancer. *ACS nano.*, **14**, 476 (2020).
172. T. Tong, H. Hu, J. Zhou, S. Deng, X. Zhang, W. Tang, L. Fang, S. Xiao and J. Liang, Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms. *Small*, **16**, 1906206 (2020).
173. C. J. Lin, L. Chang, H. W. Chu, H. J. Lin, P. C. Chang, R. Y. Wang, B. Unnikrishnan, J. Y. Mao, S. Y. Chen and C. C. Huang, High amplification of the antiviral activity of curcumin through transformation into carbon quantum dots. *Small*, **15**, 1902641 (2019).
174. A. Łoczechin, K. Seron, A. Barras, E. Giovanelli, S. Belouzard, Y. T. Chen, N. Metzler-Nolte, R. Boukherroub, J. Dubuisson and S. Szunerits, Functional carbon quantum dots as medical countermeasures to human coronavirus. *ACS Appl. Mater. Interfaces.*, **11** (46), 42964 (2019).
175. L. Zhang, P. MacKenzie, A. Cleland, E. Holmes, A. Brown and P. Simmonds, Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. *J. Virol.*, **6**, 3345 (1993).
176. A. Ali and A. C. Banerjee, Curcumin inhibits HIV-1 by promoting Tat protein degradation. *Sci. Rep.*, **6**, 1 (2016).
177. Y. Kwee, A. N. Kristanti, N. S. Aminah and M. Z. Fahmi, Design of Catechin-based Carbon Nanodots as Facile Staining Agents of Tumor Cells. *Indones. J. Chem.*, **20**, 1332 (2020).
178. Y. Kwee, A. N. Kristanti, K. Siimon, N. S. Aminah and M. Z. Fahmi, Carbon nanodots derived from natural products. *S. Afr. J. Chem.*, **75**, 40 (2021).
179. T. Du, J. Zhang, C. Li, T. Song, P. Li, J. Liu, X. Du and S. Wang, Gold/Silver Hybrid Nanoparticles with Enduring Inhibition of Coronavirus Multiplication through Multisite Mechanisms. *Bioconjugate Chem.*, **31**, 2553 (2020).
180. A. A. Yaqoob, K. Umar and M. N. M. Ibrahim, Silver nanoparticles: various methods of synthesis, size affecting factors and their potential applications—a review. *Appl. Nanosci.*, **10**, 1369 (2020).
181. D. Ting, N. Dong, L. Fang, J. Lu, J. Bi, S. Xiao and H. Han, Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. *ACS Appl. Nano Mater.*, **1**, 5451 (2018).
182. B. B. Sharma, P. Kalia, D. K. Yadava, D. Singh and T. R. Sharma, Genetics and molecular mapping of black rot resistance locus Xca1bc on chromosome B-7 in Ethiopian mustard (*Brassica carinata* A. Braun). *PLoS one.*, **11**e0152290 (2016).
183. P. Orłowski, E. Tomaszewska, M. Gniadek, P. Baska, J. Nowakowska, J. Sokolowska, Z. Nowak, M. Donten, G. Celichowski and J. Grobelny, Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection. *PLoS one*, **9**, e104113 (2014).

184. A. Kurdekar, L. A. Chunduri, E. P. Bulagonda, M. K. Haleyurgirisetty, V. Kamisetty and I. K. Hewlett, Comparative performance evaluation of carbon dot-based paper immunoassay on Whatman filter paper and nitrocellulose paper in the detection of HIV infection. *Microfluid. Nanofluid.*, **20**, 99 (2016).
185. K. S. Rao, M. K. Reddy, J. L. Horning and V. Labhasetwar, TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. *Biomaterials.*, **29**, 4429 (2008).
186. S. I. Rafiqi, S. Kumar, A. Zehra, D. Kumar, S. Jain, K. Sethi and P. K. Yadav, Nanovaccinology: Dawn of biomimetic vaccine carriers. *J. Entomol. Zool. Stud.*, **5**, 795 (2017).
187. M. J. Rotheram-Borus, D. Swendeman and G. Chovnick, The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. *Annu. Rev. Clin. Psychol.*, **5**, 143 (2009).
188. M. E. Aikins, J. Bazzill and J. J. Moon, Vaccine nanoparticles for protection against HIV infection. *Nanomedicine*, **12**, 673 (2017).
189. C. P. Karch, H. Bai, O. B. Torres, C. A. Tucker, N. L. Michael, G. R. Matyas, M. Rolland, P. Burkhard and Z. Beck, Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen. *Nanomedicine*, **16**, 206 (2019).
190. I. birma Bwatanglang, F. Mohammad and N. A. Yusof, Role of multifunctional nanomaterials in disease diagnosis and therapy. *Journal of Chemical and Pharmaceutical Research.*, **6**, 821 (2014).
191. K. J. Whaley, J. Hanes, R. Shattock, R. A. Cone and D. R. Friend, Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. *Antivir. Res.*, **88**, S55 (2010).
192. M.-G. Kim, J. Y. Park, Y. Shon, G. Kim, G. Shim and Y.-K. Oh, Nanotechnology and vaccine development. *Asian J. Pharm. Sci.*, **9**, 227 (2014).
193. A. Benlahrech, J. Harris, A. Meiser, T. Papagatsias, J. Hornig, P. Hayes, A. Lieber, T. Athanasopoulos, V. Bachy and E. Csomor, Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. *Proc. Natl. Acad. Sci. U S A*, **106**, 19940 (2009).
194. X. Jiang, M. Totrov, W. Li, J. M. Sampson, C. Williams, H. Lu, X. Wu, S. Lu, S. Wang and S. Zolla-Pazner, Rationally designed immunogens targeting HIV-1 gp120 V1V2 induce distinct conformation-specific antibody responses in rabbits. *J. Virol.*, **90**, 11007 (2016).
195. K. Slieden, G. Ozorowski, J. A. Burger, T. van Montfort, M. Stunnenberg, C. LaBranche, D. C. Montefiori, J. P. Moore, A. B. Ward and R. W. Sanders, Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity. *Retrovirology.*, **12**, 82 (2015).
196. S. P. Kasturi, I. Skountzou, R. A. Albrecht, D. Koutsonanos, T. Hua, H. I. Nakaya, R. Ravindran, S. Stewart, M. Alam and M. Kwissa, Programming the magnitude and persistence of antibody responses with innate immunity. *Nature.*, **470**, 543 (2011).
197. M. N. Swamy, H. Wu and P. Shankar, Recent advances in RNAi-based strategies for therapy and prevention of HIV-1/AIDS. *Adv. Drug Deliv. Rev.*, **103**, 174 (2016).
198. Y. Y. Aung, A. N. Kristanti, S. Q. Khairunisa, N. Nasronudin, Fahmi, M. Z. Inactivation of HIV-1 Infection through Integrative Blocking with Amino Phenylboronic Acid Attributed Carbon Dots. *ACS Biomater. Sci. eng.* **6**, 4490 (2020).